Browse by UCL people
Group by: Type | Date
Number of items: 268.
2025
|
Anker, Stefan D;
Robertson, Michele;
McMurray, John JV;
Jhund, Pardeep S;
White, Claire;
Reid, Chante;
Bhandari, Sunil;
... Ford, Ian; + view all
(2025)
Recurrent event analyses in patients receiving maintenance dialysis and the effect of higher- versus lower-dose chronic intravenous iron therapy: A report focusing on heart failure events from the PIVOTAL trial.
European Journal of Heart Failure
10.1002/ejhf.3670.
(In press).
|
|
Bakker, WM;
Heerspink, HJL;
Jongs, N;
Correa-Rotter, R;
Rossing, P;
Toto, RD;
Wheeler, DC;
... Vart, P; + view all
(2025)
Effects of Dapagliflozin on Health-Related Quality of Life in Patients with CKD.
Journal of the American Society of Nephrology
10.1681/ASN.0000000776.
(In press).
|
Briggs, Juliet;
Ralston, Elizabeth;
Wilkinson, Thomas J;
Walklin, Christy;
Mangahis, Emmanuel;
Young, Hannah ML;
Castle, Ellen M;
... Greenwood, Sharlene A; + view all
(2025)
Digital physical activity intervention via the Kidney BEAM platform in patients with polycystic kidney disease: a randomized controlled trial.
Clinical Kidney Journal
, 18
(3)
, Article sfaf041. 10.1093/ckj/sfaf041.
|
|
Garcia Sanchez, JJ;
Priest, S;
Guiang, H;
Zara, A;
Wheeler, DC;
Moura, AF;
Johnston-Webber, C;
(2025)
Response to the Letter to the Editor Entitled “IMPACT CKD – All Roads Must Not Lead to Dialysis”.
[Letter].
Kidney International Reports
, 10
(8)
pp. 2886-2887.
10.1016/j.ekir.2025.06.026.
|
|
Gonzalez, Andrea Matus;
Cazzolli, Rosanna;
Madero, Magdalena;
Evangelidis, Nicole;
Howell, Martin;
Sautenet, Benedicte;
Bernier-Jean, Amelie;
... SONG-CKD Stakeholder Workshop, Investigators; + view all
(2025)
A Core Outcome Set for Trials in CKD: Report of the Standardized Outcomes in Nephrology-Chronic Kidney Disease (SONG-CKD) Stakeholder Workshops.
American Journal of Kidney Diseases
, 85
(6)
pp. 745-753.
10.1053/j.ajkd.2024.10.013.
|
|
Habte-Asres, Hellena Hailu;
Rosenthal, Miranda;
Nitsch, Dorothea;
Wheeler, David C;
(2025)
Closing the policy gap in diabetes care for individuals with advanced CKD.
Diabetic Medicine
, 42
(2)
, Article e15381. 10.1111/dme.15381.
|
 |
|
Heerspink, HJL;
Chertow, GM;
Rossing, P;
Correa-Rotter, R;
Sjöström, CD;
Toto, RD;
Wheeler, DC;
(2025)
Effects of Dapagliflozin on Progression of Chronic Kidney Disease According to Different Rates of Pre-Trial Progression.
Clinical Journal of the American Society of Nephrology
10.2215/CJN.0000000810.
(In press).
|
|
Hughes, Anastasia;
Ju, Angela;
Cazzolli, Rosanna;
Howell, Martin;
Guha, Chandana;
Levin, Adeera;
Manera, Karine;
... Jaure, Allison; + view all
(2025)
Patient-reported outcome measures for fatigue in patients with chronic kidney disease: a systematic review.
BMJ Open
, 15
(7)
, Article e099592. 10.1136/bmjopen-2025-099592.
|
|
|
Markham-Lee, Zoe;
Bhagat-Jones, Swati;
Carlton, Jill;
Frankel, Andrew;
Fraser, Simon;
Habte-Asres, Hellena H;
Hill, Claire;
... Hills, Claire E; + view all
(2025)
Research recommendations from the 2024 Breakthrough T1D, Diabetes UK and Kidney Research UK, diabetes and kidney disease expert workshop.
Diabetic Medicine
, Article e70013. 10.1111/dme.70013.
(In press).
|
|
McDonnell, Thomas;
Kalra, Philip A;
Vuilleumier, Nicolas;
Cockwell, Paul;
Wheeler, David C;
Fraser, Simon DS;
Banks, Rosamonde E;
(2025)
The Impact of Primary Renal Diagnosis on Prognosis and the Varying Predictive Power of Albuminuria in the NURTuRE-CKD Study.
American Journal of Nephrology
, 56
(1)
pp. 1-12.
10.1159/000541770.
|
|
Mcewan, Phil;
Foos, Volker;
Roberts, Geraint;
Jenkins, Robert H;
Evans, Marc;
Wheeler, David C;
Chen, Jieling;
(2025)
Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model.
Diabetes, Obesity and Metabolism
, 27
(4)
pp. 1752-1761.
10.1111/dom.16141.
(In press).
|
|
|
Molad, Jeremy;
Miwa, Kaori;
Nash, Philip S;
Ambler, Gareth;
Best, Jonathan;
Wilson, Duncan;
Hallevi, Hen;
... Koga, Masatoshi; + view all
(2025)
Increased risk of recurrent stroke in patients with impaired kidney function: results of a pooled analysis of individual patient data from the MICON international collaboration.
Journal of Neurology, Neurosurgery and Psychiatry
10.1136/jnnp-2024-335110.
(In press).
|
|
|
Nash, PS;
Dehbi, HM;
Ahmed, N;
Arram, L;
Best, JG;
Balogun, M;
Bennett, K;
... OPTIMAS Investigators; + view all
(2025)
Anticoagulation Timing in Acute Stroke With Atrial Fibrillation According to Chronic Kidney Disease: The OPTIMAS Trial.
Stroke
, 56
(8)
pp. 1970-1979.
10.1161/STROKEAHA.125.051457.
|
|
|
Onoja, Anthony;
McDonnell, Thomas;
Annessi, Isabelle;
Banks, Rosamonde E;
Bergin, Marianne;
Cockwell, Paul;
Dusaulcy, Rodolphe;
... Geifman, Nophar; + view all
(2025)
Biomarkers of Kidney Failure and All-Cause Mortality in CKD.
Journal of the American Society of Nephrology
10.1681/ASN.0000000767.
(In press).
|
|
Oshima, M;
Buizen, L;
Jongs, N;
Levin, A;
Chertow, GM;
Wheeler, DC;
Heerspink, HJL;
... Neuen, BL; + view all
(2025)
SGLT2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials.
Clinical Journal of the American Society of Nephrology
10.2215/CJN.0000000771.
(In press).
|
|
Pogson, Cathy Margaret;
Austin, Rosalynn;
Patel, Jignesh Prakash;
Wheeler, David Collins;
(2025)
Medication review interventions for adults living with advanced chronic kidney disease: A scoping review.
British Journal of Clinical Pharmacology
, 91
(4)
pp. 1132-1156.
10.1111/bcp.16363.
|
|
|
Pollock, Carol;
Carrero, Juan-Jesus;
Kanda, Eiichiro;
Ofori-Asenso, Richard;
Chen, Hungta;
Garcia Sanchez, Juan Jose;
Pentakota, Surendra;
... Wheeler, David C; + view all
(2025)
Correction: Baseline Characteristics of the DISCOVER CKD Prospective Cohort.
[Corrigendum].
Advances in Therapy
10.1007/s12325-025-03107-9.
(In press).
|
|
Wasehuus, Victor;
Smeijer, J David;
Ambery, Phil;
Greasley, Peter J;
Wijkmark, Emma;
Wheeler, David C;
Rossing, Peter;
(2025)
Effects of combined treatment with zibotentan and dapagliflozin compared to dapagliflozin alone in patients with diabetic and non-diabetic chronic kidney disease.
Diabetes, Obesity and Metabolism
10.1111/dom.16468.
(In press).
|
 |
2024
|
Ålund, Oskar;
Unwin, Robert;
Challis, Benjamin;
Kalra, Philip A;
Taal, Maarten W;
Wheeler, David C;
Fraser, Simon DS;
... Söderberg, Magnus; + view all
(2024)
A note on performance metrics for the Kidney Failure Risk Equation.
Nephrology Dialysis Transplantation
, 39
(9)
pp. 1523-1525.
10.1093/ndt/gfae098.
|
|
Apperloo, Ellen M;
Neuen, Brendon L;
Fletcher, Robert A;
Jongs, Niels;
Anker, Stefan D;
Bhatt, Deepak L;
Butler, Javed;
... Heerspink, Hiddo JL; + view all
(2024)
Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials.
The Lancet Diabetes & Endocrinology
, 12
(8)
pp. 545-557.
10.1016/S2213-8587(24)00155-4.
|
|
Cardoza, Kathryn;
Kang, Amy;
Smyth, Brendan;
Yi, Tae Won;
Pollock, Carol;
Agarwal, Rajiv;
Bakris, George;
... Mahaffey, Kenneth W; + view all
(2024)
Geographic and racial variability in kidney, cardiovascular and safety outcomes with canagliflozin: A secondary analysis of the CREDENCE randomized trial.
Diabetes, Obesity and Metabolism
, 26
(9)
pp. 3530-3540.
10.1111/dom.15685.
|
|
Chertow, Glenn M;
Chang, Anna Marie;
Felker, G Michael;
Heise, Mark;
Velkoska, Elena;
Fellstrom, Bengt;
Charytan, David M;
... Wolf, Myles; + view all
(2024)
Author Correction: IL-6 inhibition with clazakizumab in patients receiving maintenance dialysis: a randomized phase 2b trial.
Nature Medicine
10.1038/s41591-024-03156-7.
(In press).
|
|
Correa-Rotter, Ricardo;
Wheeler, David C;
McEwan, Phil;
(2024)
The Broader Effects of Delayed Progression to End-Stage Kidney Disease: Delaying the Inevitable or a Meaningful Change?
Advances in Therapy
10.1007/s12325-024-02950-6.
(In press).
|
|
Fishbane, Steven;
Carrero, Juan-Jesus;
Kumar, Supriya;
Kanda, Eiichiro;
Hedman, Katarina;
Ofori-Asenso, Richard;
Kashihara, Naoki;
... Pecoits-Filho, Roberto; + view all
(2024)
Hyperkalemia Burden and Treatment Pathways in Patients with CKD: Findings From the DISCOVER CKD Retrospective Cohort.
Kidney360
, 5
(7)
pp. 974-986.
10.34067/KID.0000000000000468.
|
|
Fletcher, Robert A;
Herrington, William G;
Agarwal, Rajiv;
Mayne, Kaitlin J;
Arnott, Clare;
Jardine, Meg J;
Mahaffey, Kenneth W;
... Neuen, Brendon L; + view all
(2024)
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.
Clinical Journal of the American Society of Nephrology
, 19
(9)
pp. 1180-1182.
10.2215/CJN.0000000000000470.
|
|
Gansevoort, Ron T;
Wheeler, David C;
Martínez Debén, Francisco;
Speeckaert, Marijn;
Thomas, Dirk;
Berger, Mario;
Klein, Stefan;
... Schmieder, Roland E; + view all
(2024)
The soluble guanylate cyclase activator runcaciguat significantly improves albuminuria in patients with chronic kidney disease: a randomized placebo-controlled clinical trial.
Nephrology Dialysis Transplantation
10.1093/ndt/gfae261.
(In press).
|
|
Ha, Jeffrey T;
Hiremath, Swapnil;
Jun, Min;
Green, Suetonia C;
Wheeler, David C;
Coyne, Daniel W;
Perkovic, Vlado;
(2024)
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.
NEJM Evidence
, 3
(9)
pp. 1-12.
10.1056/EVIDoa2300189.
|
|
Habte-Asres, Hellena Hailu;
Hou, Chuyou;
Forbes, Angus;
Wheeler, David C;
(2024)
Organisational initiatives to improve care in the prevention and management of cardiometabolic conditions: A scoping review.
Nutrition, Metabolism and Cardiovascular Diseases
, 34
(12)
pp. 2630-2641.
10.1016/j.numecd.2024.09.004.
|
|
Habte-Asres, Hellena Hailu;
Jiang, Yutong;
Rosenthal, Miranda;
Wheeler, David Collins;
(2024)
Burden of impaired awareness of hypoglycemia in people with diabetes undergoing hemodialysis.
BMJ Open Diabetes Research & Care
, 12
(1)
, Article e003730. 10.1136/bmjdrc-2023-003730.
|
|
|
Heerspink, Hiddo;
Nolan, Stephen;
Carrero, Juan-Jesus;
Arnold, Matthew;
Pecoits-Filho, Roberto;
Sanchez, Juan Jose Garcia;
Wittbrodt, Eric;
... Wheeler, David C; + view all
(2024)
Clinical Outcomes in Patients with CKD and Rapid or Non-rapid eGFR Decline: A Report from the DISCOVER CKD Retrospective Cohort.
Advances in Therapy
, 41
(8)
pp. 3264-3277.
10.1007/s12325-024-02913-x.
|
|
Heerspink, Hiddo Jl;
Provenzano, Michele;
Vart, Priya;
Jongs, Niels;
Correa-Rotter, Ricardo;
Rossing, Peter;
Mark, Patrick B;
... Chertow, Glenn M; + view all
(2024)
Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria.
American Heart Journal
, 270
pp. 125-135.
10.1016/j.ahj.2024.02.006.
|
|
Kotwal, Sradha S;
Perkovic, Vlado;
Jardine, Meg J;
Kim, Dana;
Shah, Nasir A;
Lin, Enmoore;
Coggan, Sarah;
... GKPTN and CAPTIVATE Investigators; + view all
(2024)
The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol.
Jama Network Open
, 7
(12)
, Article e2449998. 10.1001/jamanetworkopen.2024.49998.
|
|
Lucas, Bethany J;
Cockwell, Paul;
Fraser, Simon DS;
Kalra, Philip A;
Wheeler, David C;
Taal, Maarten W;
(2024)
Associations With Baseline Blood Pressure Control in NURTuRE-CKD.
Kidney International Reports
, 9
(5)
pp. 1508-1512.
10.1016/j.ekir.2024.02.013.
|
|
|
Matus Gonzalez, Andrea;
Evangelidis, Nicole;
Howell, Martin;
Jaure, Allison;
Sautenet, Benedicte;
Madero, Magdalena;
Ashuntantang, Gloria;
... SONG-CKD, Investigators; + view all
(2024)
Outcomes for clinical trials involving adults with chronic kidney disease: a multinational Delphi survey involving patients, caregivers, and health professionals.
Nephrology Dialysis Transplantation
, 39
(8)
pp. 1310-1321.
10.1093/ndt/gfae010.
|
|
McEwan, P;
Hafner, M;
Jha, V;
Correa-Rotter, R;
Chernin, G;
De Nicola, L;
Villanueva, R;
... Garcia Sanchez, JJ; + view all
(2024)
Correction.
[Corrigendum].
Journal of Medical Economics
, 27
(1)
pp. 165-166.
10.1080/13696998.2024.2305006.
|
|
McEwan, Phil;
Davis, Jason A;
Gabb, Peter D;
Wheeler, David C;
Rossing, Peter;
Chertow, Glenn M;
Correa-Rotter, Ricardo;
... Garcia Sanchez, Juan Jose; + view all
(2024)
Dapagliflozin in chronic kidney disease: cost-effectiveness beyond the DAPA-CKD trial.
Clinical Kidney Journal
, 17
(2)
, Article sfae025. 10.1093/ckj/sfae025.
|
|
McEwan, Phil;
Gabb, Peter D;
Davis, Jason A;
Sanchez, Juan Jose Garcia;
Sjöström, C David;
Barone, Salvatore;
Kashioulis, Pavlos;
... Heerspink, Hiddo JL; + view all
(2024)
The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis.
Nephrology Dialysis Transplantation
, Article gfae106. 10.1093/ndt/gfae106.
(In press).
|
|
Nash, Philip S;
Fandler-Hoefler, Simon;
Ambler, Gareth;
Zhang, Wenpeng;
Ozkan, Hatice;
Locatelli, Martina;
Du, Yang;
... Werring, David J; + view all
(2024)
Associations of Cerebral Small Vessel Disease and Chronic Kidney Disease in Patients With Acute Intracerebral Hemorrhage: A Cross-Sectional Study.
Neurology
, 103
(2)
, Article e209540. 10.1212/WNL.0000000000209540.
|
|
Patel, Siddharth M;
Kang, Yu Mi;
Im, KyungAh;
Neuen, Brendon L;
Anker, Stefan D;
Bhatt, Deepak L;
Butler, Javed;
... Wiviott, Stephen D; + view all
(2024)
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Circulation
, 149
(23)
pp. 1789-1801.
10.1161/CIRCULATIONAHA.124.069568.
|
|
Phillips, Thomas;
Harris, Scott;
Aiyegbusi, Olalekan Lee;
Lucas, Bethany;
Benavente, Melissa;
Roderick, Paul J;
Cockwell, Paul;
... Fraser, Simon DS; + view all
(2024)
Potentially modifiable factors associated with health-related quality of life among people with chronic kidney disease: baseline findings from the National Unified Renal Translational Research Enterprise CKD (NURTuRE-CKD) cohort.
Clinical Kidney Journal
, 17
(2)
, Article sfae010. 10.1093/ckj/sfae010.
|
|
Pinter, Jule;
Smyth, Brendan;
Stuard, Stefano;
Jardine, Meg;
Wanner, Christoph;
Rossignol, Patrick;
Wheeler, David C;
... Genser, Bernd; + view all
(2024)
Impact of Dialysate and Plasma Sodium on Mortality in a Global Historical Hemodialysis Cohort.
Journal of the American Society of Nephrology
, 35
(2)
pp. 167-176.
10.1681/ASN.0000000000000262.
|
|
Pippias, M;
Alfano, G;
Kelly, DM;
Soler, MJ;
De Chiara, L;
Olanrewaju, TO;
Arruebo, S;
... Zaidi, D; + view all
(2024)
Capacity for the management of kidney failure in the International Society of Nephrology Western Europe region: report from the 2023 ISN Global Kidney Health Atlas (ISN-GKHA).
Kidney International Supplements
, 13
(1)
pp. 136-151.
10.1016/j.kisu.2024.01.008.
|
|
|
Pollock, Carol;
Carrero, Juan-Jesus;
Kanda, Eiichiro;
Ofori-Asenso, Richard;
Chen, Hungta;
Garcia Sanchez, Juan Jose;
Pentakota, Surendra;
... Wheeler, David C; + view all
(2024)
Baseline Characteristics of the DISCOVER CKD Prospective Cohort.
Advances in Therapy
10.1007/s12325-024-03028-z.
(In press).
|
|
Seidu, Samuel;
Alabraba, Vicki;
Davies, Sarah;
Newland-Jones, Philip;
Fernando, Kevin;
Bain, Stephen C;
Diggle, Jane;
... Wilding, John PH; + view all
(2024)
SGLT2 Inhibitors – The New Standard of Care for Cardiovascular, Renal and Metabolic Protection in Type 2 Diabetes: A Narrative Review.
Diabetes Therapy
10.1007/s13300-024-01550-5.
|
|
Stamellou, Eleni;
Saritas, Turgay;
Froissart, Marc;
Kronenberg, Florian;
Stenvinkel, Peter;
Wheeler, David C;
Eckardt, Kai-Uwe;
... Fotheringham, James; + view all
(2024)
Identifying individuals at risk of needing CKD associated medications in a European kidney disease cohort.
BMC Nephrology
, 25
, Article 60. 10.1186/s12882-024-03497-y.
|
|
Tangri, Navdeep;
Mathur, Vandana S;
Bushinsky, David A;
Klaerner, Gerrit;
Li, Elizabeth;
Parsell, Dawn;
Stasiv, Yuri;
... Inker, Lesley A; + view all
(2024)
VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of Chronic Kidney Disease in Patients with Metabolic Acidosis.
Journal of the American Society of Nephrology
, 35
(3)
pp. 311-320.
10.1681/ASN.0000000000000292.
|
|
Wheeler, David C;
Søndergaard, Henning;
Gwynn, Cathy;
Hedman, Katarina;
Hedberg, Jonatan;
Allum, Alaster;
Chung, Hui-Lan;
... Morris, Jon; + view all
(2024)
Randomised, blinded, cross-over evaluation of the palatability of and preference for different potassium binders in participants with chronic hyperkalaemia in the USA, Canada and Europe: the APPETIZE study.
BMJ Open
, 14
(2)
, Article e074954. 10.1136/bmjopen-2023-074954.
|
|
Young, Hannah ML;
Castle, Ellen M;
Briggs, Juliet;
Walklin, Christy;
Billany, Roseanne E;
Asgari, Elham;
Bhandari, Sunil;
... Greenwood, Sharlene A; + view all
(2024)
The development and internal pilot trial of a digital physical activity and emotional well-being intervention (Kidney BEAM) for people with chronic kidney disease.
Science Reports
, 14
(1)
, Article 700. 10.1038/s41598-023-50507-4.
|
2023
|
Beernink, Jelle M;
Persson, Frederik;
Jongs, Niels;
Laverman, Gozewijn D;
Chertow, Glenn M;
McMurray, John JV;
Langkilde, Anna Maria;
... Heerspink, Hiddo JL; + view all
(2023)
Efficacy of Dapagliflozin by Baseline Diabetes Medications: A Prespecified Analysis From the DAPA-CKD Study.
Diabetes Care
, Article dc221514. 10.2337/dc22-1514.
|
|
Bhandari, Sunil;
Parfrey, Patrick;
White, Claire;
Anker, Stefan D;
Farrington, Kenneth;
Ford, Ian;
Kalra, Philip A;
... PIVOTAL Investigators, Committees; + view all
(2023)
Predictors of quality of life in patients within the first year of commencing haemodialysis based on baseline data from the PIVOTAL trial and associations with the study outcomes.
Journal of Nephrology
, 36
pp. 1651-1662.
10.1007/s40620-023-01571-6.
|
|
Charytan, David M;
Mahaffey, Kenneth W;
Jardine, Meg J;
Cannon, Christopher P;
Neal, Bruce;
Lambers Heerspink, Hiddo J;
Agarwal, Rajiv;
... Wheeler, David C; + view all
(2023)
Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering.
BMJ Open Diabetes Research and Care
, 11
(3)
, Article e003270. 10.1136/bmjdrc-2022-003270.
|
|
|
Chertow, Glenn M;
Correa-Rotter, Ricardo;
Vart, Priya;
Jongs, Niels;
McMurray, John JV;
Rossing, Peter;
Langkilde, Anna Maria;
... DAPA‐CKD Trial Committees and Investigators; + view all
(2023)
Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial.
Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease
, 12
(9)
, Article e028739. 10.1161/JAHA.122.028739.
|
|
Desai, Nihar R;
Navaneethan, Sankar D;
Nicholas, Susanne B;
Pantalone, Kevin M;
Wanner, Christoph;
Hamacher, Stefanie;
Gay, Alain;
(2023)
Design and rationale of FINE-REAL: A prospective study of finerenone in clinical practice.
Journal of Diabetes and its Complications
, 37
(4)
, Article 108411. 10.1016/j.jdiacomp.2023.108411.
|
|
Ebert, Thomas;
Sattar, Nosheen;
Greig, Marni;
Lamina, Claudia;
Froissart, Marc;
Eckardt, Kai-Uwe;
Floege, Jürgen;
... Fotheringham, James; + view all
(2023)
Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia.
American Journal of Kidney Diseases
10.1053/j.ajkd.2023.05.010.
(In press).
|
|
Fletcher, Robert A;
Jongs, Niels;
Chertow, Glenn M;
McMurray, John JV;
Arnott, Clare;
Jardine, Meg J;
Mahaffey, Kenneth W;
... Neuen, Brendon L; + view all
(2023)
Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
Journal of the American Society of Nephrology
, 34
(12)
pp. 1965-1975.
10.1681/ASN.0000000000000248.
|
|
Garcia Sanchez, JJ;
James, G;
Carrero, JJ;
Arnold, M;
Lam, CSP;
Pollock, C;
Chen, H;
... Pecoits-Filho, R; + view all
(2023)
Health Care Resource Utilization and Related Costs of Patients With CKD From the United States: A Report From the DISCOVER CKD Retrospective Cohort.
Kidney International Reports
, 8
(4)
pp. 785-795.
10.1016/j.ekir.2023.01.037.
|
|
Greenwood, SA;
Oliveira, BA;
Asgari, E;
Ayis, S;
Baker, LA;
Beckley-Hoelscher, N;
Goubar, A;
... Bramham, K; + view all
(2023)
A Randomized Trial of Intravenous Iron Supplementation and Exercise on Exercise Capacity in Iron-Deficient Nonanemic Patients With CKD.
Kidney International Reports
10.1016/j.ekir.2023.05.002.
|
|
Greenwood, Sharlene A;
Young, Hannah ML;
Briggs, Juliet;
Castle, Ellen M;
Walklin, Christy;
Haggis, Lynda;
Balkin, Caitlin;
... Macdonald, Jamie H; + view all
(2023)
Evaluating the effect of a digital health intervention to enhance physical activity in people with chronic kidney disease (Kidney BEAM): a multicentre, randomised controlled trial in the UK.
The Lancet Digital Health
10.1016/S2589-7500(23)00204-2.
(In press).
|
|
Heerspink, Hiddo JL;
Greasley, Peter J;
Ahlström, Christine;
Althage, Magnus;
Dwyer, Jamie P;
Law, Gordon;
Wijkmark, Emma;
... Ambery, Philip; + view all
(2023)
Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial.
Nephrology Dialysis Transplantation
, Article gfad183. 10.1093/ndt/gfad183.
(In press).
|
|
|
Heerspink, Hiddo JL;
Kiyosue, Arihiro;
Wheeler, David C;
Lin, Min;
Wijkmark, Emma;
Carlson, Glenn;
Mercier, Anne-Kristina;
... Ambery, Phil; + view all
(2023)
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
The Lancet
, 402
(10416)
pp. 2004-2017.
10.1016/S0140-6736(23)02230-4.
|
|
Heerspink, Hiddo L;
Jongs, Niels;
Neuen, Brendon;
Schloemer, Patrick;
Vaduganathan, Muthiah;
Inker, Lesley;
Fletcher, Robert A;
... Perkovic, Vlado; + view all
(2023)
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials.
Kidney International
, 104
(1)
pp. 181-188.
10.1016/j.kint.2023.03.037.
|
|
Heerspink, Hiddo L;
Jongs, Niels;
Schloemer, Patrick;
Little, Dustin J;
Brinker, Meike;
Tasto, Christoph;
Karpefors, Martin;
... Gasparyan, Samvel B; + view all
(2023)
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
Journal of the American Society of Nephrology
10.1681/ASN.0000000000000243.
(In press).
|
|
|
Johansen, Kirsten L;
Cobitz, Alexander R;
Singh, Ajay K;
Macdougall, Iain C;
Lopes, Renato D;
Obrador, Gregorio T;
Kovesdy, Csaba P;
... Wheeler, David C; + view all
(2023)
The ASCEND-NHQ trial found positive effects of daprodustat on hemoglobin and quality of life in patients with non-dialysis-dependent chronic kidney disease.
Kidney International
10.1016/j.kint.2023.02.019.
(In press).
|
|
Kang, Amy;
Smyth, Brendan;
Neuen, Brendon L;
Heerspink, Hiddo JL;
Di Tanna, Gian Luca;
Zhang, Hong;
Arnott, Clare;
... Jardine, Meg J; + view all
(2023)
The sodium-glucose cotransporter-2 inhibitor canagliflozin does not increase risk of non-genital skin and soft tissue infections in people with type 2 diabetes mellitus: A pooled post hoc analysis from the CANVAS Program and CREDENCE randomized double-blind trials.
Diabetes, Obesity and Metabolism
, 25
(8)
pp. 2151-2162.
10.1111/dom.15091.
|
|
Koshino, Akihiko;
Schechter, Meir;
Chertow, Glenn M;
Vart, Priya;
Jongs, Niels;
Toto, Robert D;
Rossing, Peter;
... Heerspink, Hiddo JL; + view all
(2023)
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.
NEJM Evidence
, 2
(6)
pp. 1-10.
10.1056/EVIDoa2300049.
|
|
|
Ku, Elaine;
Del Vecchio, Lucia;
Eckardt, Kai-Uwe;
Haase, Volker H;
Johansen, Kirsten L;
Nangaku, Masaomi;
Tangri, Navdeep;
... for Conference Participants; + view all
(2023)
Novel Anemia Therapies in CKD: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
10.1016/j.kint.2023.05.009.
(In press).
|
|
Macdougall, Iain C;
Ponikowski, Piotr;
Stack, Austin G;
Wheeler, David C;
Anker, Stefan D;
Butler, Javed;
Filippatos, Gerasimos;
... Jankowska, Ewa A; + view all
(2023)
Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function.
Clinical Journal of the American Society of Nephrology
10.2215/CJN.0000000000000223.
(In press).
|
|
Mark, Patrick B;
Carrero, Juan J;
Matsushita, Kunihiro;
Sang, Yingying;
Ballew, Shoshana H;
Grams, Morgan E;
Coresh, Josef;
... Stengel, Benedicte; + view all
(2023)
Major cardiovascular events and subsequent risk of kidney failure with replacement therapy: a CKD Prognosis Consortium study.
European Heart Journal
, 44
(13)
pp. 1157-1166.
10.1093/eurheartj/ehac825.
|
|
Mathur, Vandana S;
Bushinsky, David A;
Inker, Lesley;
Klaerner, Gerrit;
Li, Elizabeth;
Parsell, Dawn;
Perkovic, Vlado;
... Tangri, Navdeep; + view all
(2023)
Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis.
Nephrology Dialysis Transplantation
, 38
(6)
pp. 1448-1458.
10.1093/ndt/gfac289.
|
|
McEwan, Phil;
Hafner, Marco;
Jha, Vivekenand;
Correa-Rotter, Ricardo;
Chernin, Gil;
De Nicola, Luca;
Villanueva, Russell;
... Garcia Sanchez, Juan Jose; + view all
(2023)
Translating the efficacy of dapagliflozin in chronic kidney disease to lower healthcare resource utilization and costs: a medical care cost offset analysis.
Journal of Medical Economics
, 26
(1)
pp. 1407-1416.
10.1080/13696998.2023.2264715.
|
|
Nash, Philip S;
Simister, Rob J;
Wheeler, David C;
Werring, David J;
(2023)
Hypertension and small vessel disease: do the drugs work?
British Journal of Hospital Medicine
, 84
(9)
10.12968/hmed.2023.0092.
|
|
O'Lone, E;
Apple, FS;
Burton, JO;
Caskey, FJ;
Craig, JC;
de Filippi, CR;
Forfang, D;
... Herzog, CA; + view all
(2023)
Defining myocardial infarction in trials of people receiving hemodialysis: consensus report from the SONG-HD MI Expert Working group.
Kidney International
, 103
(6)
pp. 1028-1037.
10.1016/j.kint.2023.02.033.
|
|
Pollock, Carol;
Sanchez, Juan Jose Garcia;
Carrero, Juan-Jesus;
Kumar, Supriya;
Pecoits-Filho, Roberto;
Lam, Carolyn S P;
Chen, Hungta;
... Wheeler, David C; + view all
(2023)
Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification.
Diabetic Medicine
, Article e15200. 10.1111/dme.15200.
(In press).
|
|
Sridhar, Vikas S;
Neuen, Brendon L;
Fletcher, Robert A;
Slee, April;
Ang, Fernando G;
Rapattoni, Wally;
Arnott, Clare;
... Levin, Adeera; + view all
(2023)
Kidney protection with canagliflozin: A combined analysis of the randomized CANVAS program and CREDENCE trials.
Diabetes, Obesity and Metabolism
10.1111/dom.15112.
(In press).
|
|
|
Sun, Dan-Qin;
Targher, Giovanni;
Byrne, Christopher D;
Wheeler, David C;
Wong, Vincent Wai-Sun;
Fan, Jian-Gao;
Tilg, Herbert;
... Zheng, Ming-Hua; + view all
(2023)
An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease.
Hepatobiliary Surgery and Nutrition
, 12
(3)
pp. 386-403.
10.21037/hbsn-22-421.
|
|
|
Taal, Maarten W;
Lucas, Bethany;
Roderick, Paul;
Cockwell, Paul;
Wheeler, David C;
Saleem, Moin A;
Fraser, Simon DS;
... Kalra, Philip A; + view all
(2023)
Associations with age and glomerular filtration rate in a referred population with chronic kidney disease: Methods and baseline data from a UK multicentre cohort study (NURTuRE-CKD).
Nephrology Dialysis Transplantation
, Article gfad110. 10.1093/ndt/gfad110.
(In press).
|
|
|
van der Hoek, Sjoukje;
Jongs, Niels;
Oshima, Megumi;
Neuen, Brendon L;
Stevens, Jasper;
Perkovic, Vlado;
Levin, Adeera;
... Heerspink, Hiddo JL; + view all
(2023)
Glycemic Control and Effects of Canagliflozin in Reducing Albuminuria and eGFR: A Post Hoc Analysis of the CREDENCE Trial.
Clinical Journal of the American Society of Nephrology
, 18
(6)
pp. 748-758.
10.2215/CJN.0000000000000161.
|
|
Vart, P;
Jongs, N;
Wheeler, DC;
Heerspink, HJL;
Langkilde, AM;
Chertow, GM;
(2023)
Omitted Study Rationale and Acknowledgment of Race as a Social Construct.
[Corrigendum].
JAMA Network Open
, 6
(5)
, Article e2319505. 10.1001/jamanetworkopen.2023.19505.
|
|
Vart, Priya;
Butt, Jawad H;
Jongs, Niels;
Schechter, Meir;
Chertow, Glenn M;
Wheeler, David C;
Pecoits-Filho, Roberto;
... Heerspink, Hiddo JL; + view all
(2023)
Efficacy and Safety of Dapagliflozin in Patients with Chronic Kidney Disease across the Spectrum of Frailty.
The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences
, Article glad181. 10.1093/gerona/glad181.
(In press).
|
|
Vart, Priya;
Jongs, Niels;
Wheeler, David C;
Heerspink, Hiddo JL;
Langkilde, Anna Maria;
Chertow, Glenn M;
(2023)
Effectiveness and Safety of Dapagliflozin for Black vs White Patients With Chronic Kidney Disease in North and South America: A Secondary Analysis of a Randomized Clinical Trial.
Jama Network Open
, 6
(4)
, Article e2310877. 10.1001/jamanetworkopen.2023.10877.
|
|
Walklin, CG;
Young, Hannah ML;
Asghari, E;
Bhandari, S;
Billany, RE;
Bishop, N;
Bramham, K;
... Greenwood, SA; + view all
(2023)
The effect of a novel, digital physical activity and emotional well-being intervention on health-related quality of life in people with chronic kidney disease: trial design and baseline data from a multicentre prospective, wait-list randomised controlled trial (kidney BEAM).
BMC Nephrology
, 24
, Article 122. 10.1186/s12882-023-03173-7.
|
|
Willigers, Bartholomeus JA;
Ouwens, Mario;
Briggs, Andrew;
Heerspink, Hiddo JL;
Pollock, Carol;
Pecoits-Filho, Roberto;
Tangri, Navdeep;
... Garcia Sanchez, Juan Jose; + view all
(2023)
The Role of Expert Opinion in Projecting Long-Term Survival Outcomes Beyond the Horizon of a Clinical Trial.
Advances in Therapy
10.1007/s12325-023-02503-3.
(In press).
|
|
Writing Group for the CKD Prognosis, Consortium;
Grams, Morgan E;
Coresh, Josef;
Matsushita, Kunihiro;
Ballew, Shoshana H;
Sang, Yingying;
Surapaneni, Aditya;
... Gansevoort, Ron T; + view all
(2023)
Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes. An Individual-Participant Data Meta-Analysis.
JAMA: Journal of the American Medical Association
, 330
(13)
pp. 1266-1277.
10.1001/jama.2023.17002.
|
 |
|
Yi, Tae Won;
Smyth, Brendan;
Di Tanna, Gian Luca;
Arnott, Clare;
Cardoza, Kathryn;
Kang, Amy;
Pollock, Carol;
... CREDENCE Trial Investigators; + view all
(2023)
Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex: A Post Hoc Analysis of the CREDENCE Randomized Clinical Trial.
American Journal of Kidney Diseases
, 82
(1)
84-96.e1.
10.1053/j.ajkd.2022.12.015.
|
|
Yi, TW;
Wong, MMY;
Neuen, BL;
Arnott, C;
Poirier, P;
Seufert, J;
Slee, A;
... Levin, A; + view all
(2023)
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: Integrated analysis from the CANVAS Program and CREDENCE trial.
Diabetes, Obesity and Metabolism
10.1111/dom.15065.
|
|
|
Yu, Margaret K;
Vart, Priya;
Jongs, Niels;
Correa-Rotter, Ricardo;
Rossing, Peter;
McMurray, John JV;
Hou, Fan-Fan;
... Chertow, Glenn M; + view all
(2023)
Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.
Journal of General Internal Medicine
10.1007/s11606-023-08397-9.
(In press).
|
2022
|
Agarwal, Rajiv;
Hauske, Sibylle Jenny;
Wheeler, David C;
Doi, Kent;
Elsaesser, Amelie;
Ritter, Ivana;
Steubl, Dominik;
(2022)
Empagliflozin and incidence of events consistent with acute kidney injury: Pooled safety analysis in >15 000 individuals.
Diabetes, Obesity and Metabolism
, 24
(7)
pp. 1390-1393.
10.1111/dom.14694.
|
|
Bottomley, Matthew J;
Beckwith, Hannah;
McMahon, Aisling;
Nation, Michael;
Wheeler, David C;
Greenwood, Sharlene;
Hughes, Jeremy;
(2022)
Research engagement by British early-career practitioners in nephrology: a multidisciplinary survey.
BMJ Open
, 12
(12)
, Article e066212. 10.1136/bmjopen-2022-066212.
|
|
Briguori, Carlo;
Mathew, Roy O;
Huang, Zhen;
Mavromatis, Kreton;
Hickson, LaTonya J;
Lau, Wei Ling;
Mathew, Anoop;
... Bangalore, Sripal; + view all
(2022)
Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIA-CKD.
Journal of the American Heart Association
, 11
(6)
, Article e022003. 10.1161/JAHA.121.022003.
|
|
Caskey, FJ;
Procter, S;
MacNeill, SJ;
Wade, J;
Taylor, J;
Rooshenas, L;
Liu, Y;
... Lane, JA; + view all
(2022)
The high-volume haemodiafiltration vs high-flux haemodialysis registry trial (H4RT): a multi-centre, unblinded, randomised, parallel-group, superiority study to compare the effectiveness and cost-effectiveness of high-volume haemodiafiltration and high-flux haemodialysis in people with kidney failure on maintenance dialysis using linkage to routine healthcare databases for outcomes.
Trials
, 23
, Article 532. 10.1186/s13063-022-06357-y.
|
|
Chertow, GM;
Vart, P;
Jongs, N;
Langkilde, AM;
McMurray, JJV;
Correa-Rotter, R;
Rossing, P;
... Heerspink, HJL; + view all
(2022)
Quételet (Body Mass) Index and Effects of Dapagliflozin in CKD.
Diabetes, Obesity and Metabolism
, 24
(5)
pp. 827-837.
10.1111/dom.14641.
|
|
Cleary, F;
Kim, L;
Prieto-Merino, D;
Wheeler, D;
Steenkamp, R;
Fluck, R;
Adlam, D;
... Nitsch, D; + view all
(2022)
Association between practice coding of chronic kidney disease (CKD) in primary care and subsequent hospitalisations and death: a cohort analysis using national audit data.
BMJ open
, 12
(10)
, Article e064513. 10.1136/bmjopen-2022-064513.
|
|
Feher, Michael;
Hinton, William;
Forbes, Anna;
Munro, Neil;
Joy, Mark;
Wheeler, David;
de Lusignan, Simon;
(2022)
Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study).
JMIR Research Protocols
, 11
(7)
, Article e34206. 10.2196/34206.
|
|
|
Forst, Thomas;
Mathieu, Chantal;
Giorgino, Francesco;
Wheeler, David C;
Papanas, Nikolaos;
Schmieder, Roland E;
Halabi, Atef;
... Tuttle, Katherine R; + view all
(2022)
New strategies to improve clinical outcomes for diabetic kidney disease.
BMC Medicine
, 20
(1)
, Article 337. 10.1186/s12916-022-02539-2.
|
|
Greenwood, Sharlene A;
Beckley-Hoelscher, Nicholas;
Asgari, Elham;
Ayis, Salma;
Baker, Luke A;
Banerjee, Debasish;
Bhandari, Sunil;
... Macdougall, Iain C; + view all
(2022)
The effect of intravenous iron supplementation on exercise capacity in iron-deficient but not anaemic patients with chronic kidney disease: study design and baseline data for a multicentre prospective double-blind randomised controlled trial.
BMC Nephrology
, 23
(1)
, Article 268. 10.1186/s12882-022-02896-3.
|
|
|
Hailu Habte-Asres, Hellena;
Murrells, Trevor;
Nitsch, Dorothea;
Wheeler, David C;
Forbes, Angus;
(2022)
Glycaemic variability and progression of chronic kidney disease in people with diabetes and comorbid kidney disease: Retrospective cohort study.
Diabetes Research and Clinical Practice
, 193
, Article 110117. 10.1016/j.diabres.2022.110117.
|
|
Heerspink, Hiddo JL;
Chertow, Glenn M;
Jongs, Niels;
Correa-Rotter, Ricardo;
Rossing, Peter;
Sjostrom, C David;
Langkilde, Anna Maria;
(2022)
Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria.
Clinical Journal of the American Society of Nephrology
, 17
(10)
, Article 07290622. 10.2215/CJN.07290622.
|
|
Heerspink, HJL;
Oshima, M;
Zhang, H;
Li, J;
Agarwal, R;
Capuano, G;
Charytan, DM;
... Jardine, MJ; + view all
(2022)
Canagliflozin Reduces Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
American Journal of Kidney Diseases
, 79
(2)
244-256.e1.
10.1053/j.ajkd.2021.05.005.
|
|
James, G;
Garcia Sanchez, JJ;
Carrero, JJ;
Kumar, S;
Pecoits-Filho, R;
Heerspink, HJL;
Nolan, S;
... Wheeler, DC; + view all
(2022)
Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility.
Kidney International Reports
10.1016/j.ekir.2022.05.033.
(In press).
|
|
|
Jongs, Niels;
Chertow, Glenn M;
Greene, Tom;
McMurray, John JV;
Langkilde, Anna Maria;
Correa-Rotter, Ricardo;
Kashihara, Naoki;
... DAPA-CKD Trial Committees and Investigators, .; + view all
(2022)
Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD.
Journal of the American Society of Nephrology
, 33
(10)
, Article 2022030306. 10.1681/ASN.2022030306.
|
|
Lalayiannis, AD;
Crabtree, NJ;
Ferro, CJ;
Wheeler, DC;
Duncan, ND;
Smith, C;
Popoola, J;
... Shroff, R; + view all
(2022)
Bone Mineral Density and Vascular Calcification in Children and Young Adults With CKD 4 to 5 or on Dialysis.
Kidney International Reports
10.1016/j.ekir.2022.10.023.
(In press).
|
|
Lalayiannis, Alexander D;
Ferro, Charles J;
Wheeler, David C;
Duncan, Neill D;
Smith, Colette;
Popoola, Joyce;
Askiti, Varvara;
... Shroff, Rukshana; + view all
(2022)
The burden of subclinical cardiovascular disease in children and young adults with chronic kidney disease and on dialysis.
Clinical Kidney Journal
, 15
(2)
pp. 287-294.
10.1093/ckj/sfab168.
|
|
|
Li, Jing-Wei;
Arnott, Clare;
Heerspink, Hiddo JL;
MBiostat, Qiang Li;
Cannon, Christopher P;
Wheeler, David C;
Charytan, David M;
... Jardine, Meg J; + view all
(2022)
Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial.
Journal of the American Heart Association Cardiovascular and Cerebrovascular Disease
, 11
(16)
, Article e025045. 10.1161/JAHA.121.025045.
|
|
|
Liao, Jinlan;
Kang, Amy;
Xia, Chao;
Young, Tamara;
Tanna, Gian Luca Di;
Arnott, Clare;
Pollock, Carol;
... Smyth, Brendan; + view all
(2022)
The impact of canagliflozin on the risk of neuropathy events: a post-hoc exploratory analysis of the CREDENCE trial.
Diabetes & Metabolism
, 48
(4)
, Article 101331. 10.1016/j.diabet.2022.101331.
|
|
Lv, Jicheng;
Wong, Muh Geot;
Hladunewich, Michelle A;
Jha, Vivekanand;
Hooi, Lai Seong;
Monaghan, Helen;
Zhao, Minghui;
... TESTING Study Group; + view all
(2022)
Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
Journal of the American Medical Association
, 327
(19)
pp. 1888-1898.
10.1001/jama.2022.5368.
|
|
McEwan, Phil;
Boyce, Rebecca;
Sanchez, Juan Jose Garcia;
Sjöström, C David;
Stefansson, Bergur;
Nolan, Stephen;
Correa-Rotter, Ricardo;
... Heerspink, Hiddo JL; + view all
(2022)
Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis.
Nephrology Dialysis Transplantation
10.1093/ndt/gfac280.
(In press).
|
|
McEwan, Phil;
Darlington, Oliver;
Miller, Ryan;
McMurray, John JV;
Wheeler, David C;
Heerspink, Hiddo JL;
Briggs, Andrew;
... Garcia Sanchez, Juan Jose; + view all
(2022)
Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD.
Clinical Journal of the American Society of Nephrology
, 17
(12)
pp. 1730-1741.
10.2215/CJN.03790322.
|
|
Neuen, Brendon L;
Oshima, Megumi;
Agarwal, Rajiv;
Arnott, Clare;
Cherney, David Z;
Edwards, Robert;
Langkilde, Anna Maria;
... Heerspink, Hiddo JL; + view all
(2022)
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Circulation
, 145
(9)
pp. 1460-1470.
10.1161/CIRCULATIONAHA.121.057736.
|
|
Pollock, Carol;
James, Glen;
Garcia Sanchez, Juan Jose;
Carrero, Juan Jesus;
Arnold, Matthew;
Lam, Carolyn SP;
Chen, Hungta Tony;
... Wheeler, David C; + view all
(2022)
Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort.
Clinical Kidney Journal
10.1093/ckj/sfac168.
(In press).
|
|
Provenzano, Michele;
Jongs, Niels;
Vart, Priya;
Stefánsson, Bergur V;
Chertow, Glenn M;
Langkilde, Anna Maria;
McMurray, John JV;
... DAPA-CKD Trial Committees and Investigators; + view all
(2022)
The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists.
Kidney International Reports
, 7
(3)
pp. 436-443.
10.1016/j.ekir.2021.12.013.
|
|
Rossing, P;
Inzucchi, SE;
Vart, P;
Jongs, N;
Docherty, KF;
Jhund, PS;
Kober, L;
... Heerspink, HJL; + view all
(2022)
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials.
Lancet Diabetes and Endocrinology
, 10
(1)
pp. 24-34.
10.1016/S2213-8587(21)00295-3.
|
|
Schechter, Meir;
Jongs, Niels;
Chertow, Glenn M;
Mosenzon, Ofri;
McMurray, John JV;
Correa-Rotter, Ricardo;
Rossing, Peter;
... Heerspink, Hiddo JL; + view all
(2022)
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.
Annals of Internal Medicine
10.7326/M22-2115.
(In press).
|
|
Singh, Ajay K;
Cizman, Borut;
Carroll, Kevin;
McMurray, John J;
Perkovic, Vlado;
Jha, Vivekanand;
Johansen, Kirsten L;
... Solomon, Scott; + view all
(2022)
Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients A Randomized Clinical Trial.
JAMA Internal Medicine
10.1001/jamainternmed.2022.0605.
(In press).
|
|
Thomson, PC;
Mark, PB;
Robertson, M;
White, C;
Anker, SD;
Bhandari, S;
Farrington, K;
... Andani, S; + view all
(2022)
An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial.
Kidney International Reports
10.1016/j.ekir.2022.05.008.
(In press).
|
|
Tuttle, Katherine R;
Levin, Adeera;
Nangaku, Masaomi;
Kadowaki, Takashi;
Agarwal, Rajiv;
Hauske, Sibylle J;
Elsäßer, Amelie;
... Wheeler, David C; + view all
(2022)
Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials.
Diabetes Care
, Article dc212034. 10.2337/dc21-2034.
|
|
Vart, Priya;
Correa-Rotter, Ricardo;
Hou, Fan Fan;
Jongs, Niels;
Chertow, Glenn M;
Langkilde, Anna Maria;
McMurray, John JV;
... Heerspink, Hiddo JL; + view all
(2022)
Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions.
Kidney International Reports
, 7
(4)
pp. 699-707.
10.1016/j.ekir.2022.01.1060.
|
|
Vart, Priya;
Vaduganathan, Muthiah;
Jongs, Niels;
Remuzzi, Giuseppe;
Wheeler, David C;
Hou, Fan Fan;
McCausland, Finnian;
... Heerspink, Hiddo JL; + view all
(2022)
Estimated Lifetime Benefit of Combined RAAS and SGLT2 Inhibitor Therapy in Patients with Albuminuric CKD without Diabetes.
Clinical Journal of the American Society of Nephrology
, 17
(12)
pp. 1754-1762.
10.2215/CJN.08900722.
|
|
Waijer, Simke W;
Vart, Priya;
Cherney, David Z;
Chertow, Glenn M;
Jongs, Niels;
Langkilde, Anna Maria;
Mann, Johannes FE;
... Heerspink, Hiddo JL; + view all
(2022)
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Diabetologia
10.1007/s00125-022-05694-6.
(In press).
|
|
Wilding, JPH;
Evans, M;
Fernando, K;
Gorriz, JL;
Cebrian, A;
Diggle, J;
Hicks, D;
... Del Prato, S; + view all
(2022)
The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review.
Diabetes Therapy
10.1007/s13300-022-01228-w.
(In press).
|
|
|
Young, Tamara K;
Toussaint, Nigel D;
Di Tanna, Gian Luca;
Arnott, Clare;
Hockham, Carinna;
Kang, Amy;
Schutte, Aletta E;
... Jardine, Meg J; + view all
(2022)
Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial.
Journal of Diabetes Research
, 2022
, Article 9998891. 10.1155/2022/9998891.
|
2021
|
Bjornstad, P;
Greasley, PJ;
Wheeler, DC;
Chertow, GM;
Langkilde, AM;
Heerspink, HJL;
van Raalte, DH;
(2021)
The potential roles of osmotic and non-osmotic sodium handling in mediating effects of SGLT2 inhibitors on heart failure.
Journal of Cardiac Failure
10.1016/j.cardfail.2021.07.003.
(In press).
|
|
|
Cardoza, Kathryn;
Kang, Amy;
Smyth, Brendan;
Yi, Tae Won;
Di Tanna, Gian Luca;
Pollock, Carol A;
De Zeeuw, Dick;
... Mahaffey, Kenneth W; + view all
(2021)
133-LB: Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE.
Presented at: 81st Scientific Sessions, Virtual.
|
|
Chertow, GM;
Vart, P;
Jongs, N;
Toto, RD;
Gorriz, JL;
Hou, FF;
McMurray, JJV;
... DAPA-CKD Trial Committees and Investigators, .; + view all
(2021)
Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease.
Journal of the American Society of Nephrology
, 32
(9)
pp. 2352-2361.
10.1681/ASN.2021020167.
|
|
|
Dritsoula, A;
Kislikova, M;
Oomatia, A;
Webster, AP;
Beck, S;
Ponticos, M;
Lindsey, B;
... Caplin, B; + view all
(2021)
Epigenome-wide methylation profile of chronic kidney disease-derived arterial DNA uncovers novel pathways in disease-associated cardiovascular pathology.
Epigenetics
, 16
(7)
pp. 718-728.
10.1080/15592294.2020.1819666.
|
|
Ebert, T;
Qureshi, AR;
Lamina, C;
Fotheringham, J;
Froissart, M;
Eckardt, KU;
Wheeler, DC;
... Stenvinkel, P; + view all
(2021)
Time-dependent lipid profile inversely associates with mortality in hemodialysis patients – independent of inflammation/malnutrition.
Journal of Internal Medicine
10.1111/joim.13291.
|
|
|
Edwards, NC;
Price, AM;
Mehta, S;
Hiemstra, TF;
Kaur, A;
Greasley, PJ;
Webb, DJ;
... Townend, JN; + view all
(2021)
Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.
Clinical Journal of the American Society of Nephrology
, 16
(10)
pp. 1491-1501.
10.2215/CJN.01930221.
|
|
Evangelidis, N;
Sautenet, B;
Madero, M;
Tong, A;
Ashuntantang, G;
Sanabria, LC;
de Boer, IH;
... Craig, JC; + view all
(2021)
Standardised Outcomes in Nephrology - Chronic Kidney Disease (SONG-CKD): a protocol for establishing a core outcome set for adults with chronic kidney disease who do not require kidney replacement therapy.
Trials
, 22
(1)
, Article 612. 10.1186/s13063-021-05574-1.
|
|
|
Evangelidis, N;
Sautenet, B;
Manera, KE;
Howell, M;
Craig, JC;
Viecelli, AK;
O'Lone, E;
... SONG-HD and SONG-PD initiative; + view all
(2021)
Perspectives on blood pressure by patients on haemo- and peritoneal dialysis.
Nephrology
, 26
(1)
pp. 62-69.
10.1111/nep.13775.
|
|
Evans, RDR;
Smyth, B;
Levin, A;
Jha, V;
Wheeler, DC;
Jardine, M;
Perkovic, V;
... Hiemstra, T; + view all
(2021)
The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals.
Kidney International
, 99
(3)
pp. 551-554.
10.1016/j.kint.2020.10.048.
|
|
Fotheringham, J;
Latimer, N;
Froissart, M;
Kronenberg, F;
Stenvinkel, P;
Floege, J;
Eckardt, K-U;
(2021)
Survival on four compared with three times per week haemodialysis in high ultrafiltration patients: an observational study.
Clinical Kidney Journal
, 14
(2)
pp. 665-672.
10.1093/ckj/sfaa250.
|
|
|
Greenwood, SA;
Koufaki, P;
Macdonald, J;
Bhandari, S;
Burton, J;
Dasgupta, I;
Farrington, K;
... Mercer, TH; + view all
(2021)
The PrEscription of intraDialytic exercise to improve quAlity of Life in patients with chronic kidney disease trial: study design and baseline data for a multicentre randomized controlled trial.
Clinical Kidney Journal
, 14
(5)
pp. 1345-1355.
10.1093/ckj/sfaa107.
|
|
|
Greenwood, SA;
Koufaki, P;
Macdonald, JH;
Bhandari, S;
Burton, JO;
Dasgupta, I;
Farrington, K;
... Mercer, TH; + view all
(2021)
Randomized Trial—PrEscription of intraDialytic exercise to improve quAlity of Life in Patients Receiving Hemodialysis.
Kidney International Reports
10.1016/j.ekir.2021.05.034.
(In press).
|
|
|
Greenwood, SA;
Koufaki, P;
Macdonald, JH;
Bulley, C;
Bhandari, S;
Burton, JO;
Dasgupta, I;
... Mercer, TH; + view all
(2021)
Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT.
Health Technology Assessment
, 25
(40)
10.3310/hta25400.
|
|
|
Heerspink, HJ;
Cherney, D;
Postmus, D;
Stefánsson, BV;
Chertow, GM;
Dwyer, JP;
Greene, T;
... DAPA-CKD trial committees and investigators; + view all
(2021)
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Kidney International
10.1016/j.kint.2021.09.005.
(In press).
|
|
|
Heerspink, HJL;
Jongs, N;
Chertow, GM;
Langkilde, AM;
McMurray, JJV;
Correa-Rotter, R;
Rossing, P;
... DAPA-CKD Trial Committees and Investigators, .; + view all
(2021)
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Lancet Diabetes Endocrinol
, 9
(11)
pp. 743-754.
10.1016/S2213-8587(21)00242-4.
|
|
Heerspink, HJL;
Langkilde, A-M;
Wheeler, DC;
(2021)
Dapagliflozin in Patients with Chronic Kidney Disease.
New England Journal of Medicine
, 384
(4)
pp. 389-390.
10.1056/NEJMc2032809.
|
|
Heerspink, HJL;
Sjöström, CD;
Jongs, N;
Chertow, GM;
Kosiborod, M;
Hou, FF;
McMurray, JJV;
... DAPA-CKD Trial Committees and Investigators; + view all
(2021)
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial.
European Heart Journal
, 42
(13)
pp. 1216-1227.
10.1093/eurheartj/ehab094.
|
|
|
Ishida, JH;
Chauhan, C;
Gillespie, B;
Gruchalla, K;
McCullough, PA;
Quella, S;
Romero, A;
... Herzog, CA; + view all
(2021)
Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease.
Clinical Journal of the American Society of Nephrology
, 16
(5)
10.2215/CJN.17561120.
|
|
|
Jardine, M;
Zhou, Z;
Lambers Heerspink, HJ;
Hockham, C;
Li, Q;
Agarwal, R;
Bakris, GL;
... Perkovic, V; + view all
(2021)
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
Clinical Journal of the American Society of Nephrology
, 16
(2)
, Article 15260920. 10.2215/CJN.15260920.
|
    |
|
Jhund, PS;
Petrie, MC;
Robertson, M;
Mark, PB;
MacDonald, MR;
Connolly, E;
Anker, SD;
... PIVOTAL Investigators and Committees, .; + view all
(2021)
Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy.
JACC: Heart Failure
, 9
(7)
pp. 518-527.
10.1016/j.jchf.2021.04.005.
|
|
Jongs, N;
Greene, T;
Chertow, GM;
McMurray, JJV;
Langkilde, AM;
Correa-Rotter, R;
Rossing, P;
... DAPA-CKD Trial Committees and Investigators, .; + view all
(2021)
Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
Lancet Diabetes and Endocrinology
, 9
(11)
pp. 755-766.
10.1016/S2213-8587(21)00243-6.
|
|
Lalayiannis, AD;
Crabtree, NJ;
Ferro, CJ;
Askiti, V;
Mitsioni, A;
Biassoni, L;
Kaur, A;
... Shroff, R; + view all
(2021)
Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney disease.
Nephrology Dialysis Transplantation
, 36
(10)
pp. 1872-1881.
10.1093/ndt/gfaa199.
|
|
Liao, Jinlan;
Kang, Amy;
Xia, Chao;
Arnott, Clare;
Di Tanna, Gian Luca;
Krishnan, Arun V;
Pollock, Carol A;
... Smyth, Brendan; + view all
(2021)
131-LB: The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial.
Presented at: 81st Scientific Sessions, Virtual.
|
|
Mark, Patrick B;
Jhund, Pardeep S;
Walters, Matthew R;
Petrie, Mark C;
Power, Albert;
White, Claire;
Robertson, Michele;
... Ford, Ian; + view all
(2021)
Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial.
Kidney360
, 2
(11)
pp. 1761-1769.
10.34067/KID.0004272021.
|
|
McMurray, JJV;
Wheeler, DC;
Stefánsson, BV;
Jongs, N;
Postmus, D;
Correa-Rotter, R;
Chertow, GM;
... DAPA-CKD Trial Committees and Investigators; + view all
(2021)
Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure.
JACC: Heart Failure
10.1016/j.jchf.2021.06.017.
(In press).
|
|
|
McMurray, JJV;
Wheeler, DC;
Stefánsson, BV;
Jongs, N;
Postmus, D;
Correa-Rotter, R;
Chertow, GM;
... DAPA-CKD Trial Committees and Investigators; + view all
(2021)
Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease.
Circulation
, 143
(5)
pp. 438-448.
10.1161/CIRCULATIONAHA.120.051675.
|
|
Neuen, BL;
Ohkuma, T;
Neal, B;
Matthews, DR;
de Zeeuw, D;
Mahaffey, KW;
Fulcher, G;
... Wheeler, DC; + view all
(2021)
Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.
American Journal of Kidney Diseases
, 77
(1)
23-34.e1.
10.1053/j.ajkd.2020.06.018.
|
|
Neuen, BL;
Oshima, M;
Perkovic, V;
Agarwal, R;
Arnott, C;
Bakris, G;
Cannon, CP;
... Heerspink, HJL; + view all
(2021)
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
European Heart Journal
, 42
(48)
pp. 4891-4901.
10.1093/eurheartj/ehab497.
|
|
Pecoits-Filho, R;
James, G;
Carrero, JJ;
Wittbrodt, E;
Fishbane, S;
Sultan, AA;
Heerspink, HJL;
... Wheeler, DC; + view all
(2021)
Methods and rationale of the DISCOVER CKD global observational study.
Clinical Kidney Journal
, 14
(6)
pp. 1570-1578.
10.1093/ckj/sfab046.
|
|
|
Perkovic, V;
Blackorby, A;
Cizman, B;
Carroll, K;
Cobitz, AR;
Davies, R;
DiMino, TL;
... Singh, AK; + view all
(2021)
The ASCEND-ND trial: Study design and participant characteristics.
Nephrology Dialysis Transplantation
10.1093/ndt/gfab318.
(In press).
|
|
|
Persson, Frederik;
Rossing, Peter;
Vart, Priya;
Chertow, Glenn M;
Hou, Fan Fan;
McMurray, John J;
Correa-Rotter, Ricardo;
... Heerspink, Hiddo L; + view all
(2021)
317-OR: Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial.
Presented at: 81st Virtual Scientific Sessions, Virtual.
|
|
Persson, F;
Rossing, P;
Vart, P;
Chertow, GM;
Hou, FF;
Jongs, N;
McMurray, JJV;
... DAPA-CKD Trial Committees and Investigators; + view all
(2021)
Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial.
Diabetes Care
, 44
(6)
, Article dc210300. 10.2337/dc21-0300.
|
|
Petrie, MC;
Jhund, PS;
Connolly, E;
Mark, PB;
MacDonald, MR;
Robertson, M;
Anker, SD;
... PIVOTAL Investigators and Committees; + view all
(2021)
High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis.
Cardiovascular Research
10.1093/cvr/cvab317.
(In press).
|
|
Rossing, Peter;
Vart, Priya;
Chertow, Glenn M;
Hou, Fan Fan;
Jongs, Niels;
Mcmurray, John J;
Correa-Rotter, Ricardo;
... Heerspink, Hiddo L; + view all
(2021)
130-LB: Dapagliflozin and the Incidence of Type 2 Diabetes in Patients with Chronic Kidney Disease.
Presented at: 81st Scientific Sessions, Virtual.
|
|
Sarraju, A;
Li, J;
Cannon, CP;
Chang, TI;
Agarwal, R;
Bakris, G;
Charytan, DM;
... Mahaffey, KW; + view all
(2021)
Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.
American Heart Journal
, 233
pp. 141-148.
10.1016/j.ahj.2020.12.008.
|
|
Singh, AK;
Carroll, K;
McMurray, JJ;
Solomon, S;
Jha, V;
Johansen, KL;
Lopes, RD;
... Perkovic, V; + view all
(2021)
Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis.
The New England Journal of Medicine
, 385
pp. 2313-2324.
10.1056/NEJMoa2113380.
|
|
Singh, AK;
Carroll, K;
Perkovic, V;
Solomon, S;
Jha, V;
Johansen, KL;
Lopes, RD;
... McMurray, JJ; + view all
(2021)
Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis.
New England Journal of Medicine
, 385
pp. 2325-2335.
10.1056/NEJMoa2113379.
|
|
Singh, AK;
Blackorby, A;
Cizman, B;
Carroll, K;
Cobitz, AR;
Davies, R;
Jha, V;
... Wiecek, A; + view all
(2021)
Study design and baseline characteristics of patients on dialysis in the ASCEND-D trial.
Nephrology Dialysis Transplantation
10.1093/ndt/gfab065.
(In press).
|
|
|
Stefánsson, BV;
Heerspink, HJL;
Wheeler, DC;
Sjöström, CD;
Greasley, PJ;
Sartipy, P;
Cain, V;
(2021)
Data from a pooled post hoc analysis of 14 placebo-controlled, dapagliflozin treatment studies in patients with type 2 diabetes with and without anemia at baseline.
Data Brief
, 37
, Article 107237. 10.1016/j.dib.2021.107237.
|
|
|
Wheeler, DC;
(2021)
Chlorthalidone in Advanced Chronic Kidney Disease - Have We Missed a Trick?
New England Journal of Medicine
, 385
(27)
pp. 2574-2575.
10.1056/NEJMe2118149.
|
|
Wheeler, DC;
Jongs, N;
Stefansson, BV;
Chertow, GM;
Greene, T;
Hou, FF;
Langkilde, AM;
... DAPA-CKD Trial Committees and Investigators; + view all
(2021)
Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: A prespecified analysis of the DAPA-CKD trial.
Nephrology Dialysis Transplantation
10.1093/ndt/gfab335.
(In press).
|
|
|
Wheeler, DC;
Stefansson, B;
Jongs, N;
Chertow, GM;
Greene, T;
Hou, FF;
McMurray, JJ;
... Heerspink, HJL; + view all
(2021)
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Lancet Diabetes & Endocrinology
, 9
(1)
pp. 22-31.
10.1016/S2213-8587(20)30369-7.
|
|
Wheeler, DC;
Toto, RD;
Stefansson, BV;
Jongs, N;
Chertow, GM;
Greene, T;
Hou, FF;
... DAPA-CKD Trial Committees and Investigators; + view all
(2021)
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.
Kidney International
10.1016/j.kint.2021.03.033.
(In press).
|
|
|
Wong, MG;
Lv, J;
Hladunewich, MA;
Jha, V;
Hooi, LS;
Monaghan, H;
Zhao, M;
... TESTING Study Group; + view all
(2021)
The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics.
American Journal of Nephrology
pp. 1-10.
10.1159/000519812.
|
|
|
Ye, N;
Jardine, MJ;
Oshima, M;
Hockham, C;
Heerspink, HJL;
Agarwal, R;
Bakris, G;
... Neuen, BL; + view all
(2021)
Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights from the CREDENCE Trial.
Circulation
, 143
(18)
pp. 1735-1749.
10.1161/CIRCULATIONAHA.120.048740.
|
|
Yi, Tae Won;
Smyth, Brendan;
Kang, Amy;
Cardoza, Kathryn;
Di Tanna, Gian Luca;
Arnott, Clare;
Pollock, Carol A;
... Jardine, Meg J; + view all
(2021)
129-LB: Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial.
Presented at: 81st Scientific Sessions, Virtual.
|
2020
|
Bakris, G;
Oshima, M;
Mahaffey, KW;
Agarwal, R;
Cannon, CP;
Capuano, G;
Charytan, DM;
... Perkovic, V; + view all
(2020)
Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m²: Subgroup Analysis of the Randomized CREDENCE Trial.
Clinical Journal of the American Society of Nephrology
10.2215/CJN.10140620.
|
|
|
Cannon, CP;
Perkovic, V;
Agarwal, R;
Baldassarre, J;
Bakris, G;
Charytan, DM;
De Zeeuw, D;
... Mahaffey, KW; + view all
(2020)
Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.
Circulation
, 141
(5)
pp. 407-410.
10.1161/CIRCULATIONAHA.119.044359.
|
|
Cosentino, F;
Grant, PJ;
Aboyans, V;
Bailey, CJ;
Ceriello, A;
Delgado, V;
Federici, M;
... ESC Scientific Document Group, .; + view all
(2020)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
European Heart Journal
, 41
(2)
10.1093/eurheartj/ehz486.
|
|
Fotheringham, J;
Smith, MT;
Froissart, M;
Kronenberg, F;
Stenvinkel, P;
Floege, J;
Eckardt, K-U;
(2020)
Hospitalization and mortality following non-attendance for hemodialysis according to dialysis day of the week: a European cohort study.
BMC Nephrology
, 21
, Article 218. 10.1186/s12882-020-01874-x.
|
|
|
Gonzalez, AM;
Gutman, T;
Lopez-Vargas, P;
Anumudu, S;
Arce, CM;
Craig, JC;
Dunn, L;
... Tong, A; + view all
(2020)
Patient and Caregiver Priorities for Outcomes in CKD: A Multinational Nominal Group Technique Study.
American Journal of Kidney Diseases
, 76
(5)
pp. 679-689.
10.1053/j.ajkd.2020.03.022.
|
|
Heerspink, HJL;
Stefansson, BV;
Chertow, GM;
Correa-Rotter, R;
Greene, T;
Hou, F-F;
Lindberg, M;
... DAPA-CKD Investigators; + view all
(2020)
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
Nephrology Dialysis Transplantation
, 35
(2)
pp. 274-282.
10.1093/ndt/gfz290.
|
|
Heerspink, HJL;
Stefánsson, BV;
Correa-Rotter, R;
Chertow, GM;
Greene, T;
Hou, F-F;
Mann, JFE;
... DAPA-CKD Trial Committees and Investigators; + view all
(2020)
Dapagliflozin in Patients with Chronic Kidney Disease.
The New England Journal of Medicine
, 383
pp. 1436-1446.
10.1056/NEJMoa2024816.
|
|
Jardine, MJ;
Zhou, Z;
Mahaffey, KW;
Oshima, M;
Agarwal, R;
Bakris, G;
Bajaj, HS;
... CREDENCE Study Investigators; + view all
(2020)
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial.
Journal of the American Society of Nephrology (JASN)
, 31
(5)
pp. 1128-1139.
10.1681/ASN.2019111168.
|
|
|
Lamina, C;
Kronenberg, F;
Stenvinkel, P;
Froissart, M;
Forer, L;
Schönherr, S;
Wheeler, DC;
... Floege, J; + view all
(2020)
Association of changes in bone mineral parameters with mortality in haemodialysis patients: insights from the ARO cohort.
Nephrology Dialysis Transplantation
, 35
(3)
pp. 478-487.
10.1093/ndt/gfz060.
|
|
Levin, A;
Agarwal, R;
Herrington, WG;
Heerspink, HL;
Mann, JFE;
Shahinfar, S;
Tuttle, KR;
... participant authors of the International Society of Nephrology’s; + view all
(2020)
International consensus definitions of clinical trial outcomes for kidney failure: 2020.
Kidney International
, 98
(4)
pp. 849-859.
10.1016/j.kint.2020.07.013.
|
|
|
Levin, A;
Perkovic, V;
Wheeler, DC;
Hantel, S;
George, JT;
von Eynatten, M;
Koitka-Weber, A;
... EMPA-REG OUTCOME Investigators; + view all
(2020)
Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial.
Clinical Journal of the American Society of Nephrology
, 15
(10)
pp. 1433-1444.
10.2215/CJN.14901219.
|
|
|
Macdougall, IC;
Bhandari, S;
White, C;
Anker, SD;
Farrington, K;
Kalra, PA;
Mark, PB;
... PIVOTAL investigators and committees; + view all
(2020)
Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial.
Journal of the American Society of Nephrology (JASN)
, 31
(5)
pp. 1118-1127.
10.1681/ASN.2019090972.
|
        |
|
Małyszko, J;
Bamias, A;
Danesh, FR;
Dębska-Ślizień, A;
Gallieni, M;
Gertz, MA;
Kielstein, JT;
... Conference Participants; + view all
(2020)
KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation.
Kidney International
, 98
(6)
pp. 1407-1418.
10.1016/j.kint.2020.07.012.
|
|
|
Mccafferty, K;
Caplin, B;
Knight, S;
Hockings, P;
Wheeler, D;
Fan, SL;
Hulthe, J;
... Yaqoob, MM; + view all
(2020)
HEROIC: a 5-year observational cohort study aimed at identifying novel factors that drive diabetic kidney disease: rationale and study protocol.
BMJ Open
, 10
(9)
, Article e033923. 10.1136/bmjopen-2019-033923.
|
|
|
O'Lone, E;
Howell, M;
Viecelli, AK;
Craig, JC;
Tong, A;
Sautenet, B;
Herrington, WG;
... Wheeler, DC; + view all
(2020)
Identifying critically important cardiovascular outcomes for trials in hemodialysis: an international survey with patients, caregivers and health professionals.
Nephrology Dialysis Transplantation
, 35
(10)
pp. 1761-1769.
10.1093/ndt/gfaa008.
|
|
O'Lone, E;
Viecelli, AK;
Craig, JC;
Tong, A;
Sautenet, B;
Herrington, WG;
Herzog, CA;
... SONG-HD CVD Consensus Workshop Investigators; + view all
(2020)
Establishing Core Cardiovascular Outcome Measures for Trials in Hemodialysis: Report of an International Consensus Workshop.
American Journal of Kidney Diseases
, 76
(1)
pp. 109-120.
10.1053/j.ajkd.2020.01.022.
|
|
Oshima, M;
Jardine, MJ;
Agarwal, R;
Bakris, G;
Cannon, CP;
Charytan, DM;
de Zeeuw, D;
... Heerspink, HJL; + view all
(2020)
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.
Kidney International
10.1016/j.kint.2020.10.042.
(In press).
|
|
|
Oshima, M;
Neuen, BL;
Jardine, MJ;
Bakris, G;
Edwards, R;
Levin, A;
Mahaffey, KW;
... Heerspink, HJL; + view all
(2020)
Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.
The Lancet Diabetes & Endocrinology
, 8
(11)
pp. 903-914.
10.1016/S2213-8587(20)30300-4.
|
|
Oshima, M;
Neuen, BL;
Li, J;
Perkovic, V;
Charytan, DM;
de Zeeuw, D;
Edwards, R;
... Heerspink, HJL; + view all
(2020)
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial.
Journal of the American Society of Nephrology
10.1681/ASN.2020050723.
(In press).
|
|
|
Porta, C;
Bamias, A;
Danesh, FR;
Dębska-Ślizień, A;
Gallieni, M;
Gertz, MA;
Kielstein, JT;
... Conference Participants, .; + view all
(2020)
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer.
Kidney International
, 98
(5)
pp. 1108-1119.
10.1016/j.kint.2020.06.046.
|
|
|
Ramesh, S;
James, MT;
Holroyd-Leduc, JM;
Wilton, SB;
Seely, EW;
Hemmelgarn, BR;
Tonelli, M;
... Ahmed, SB; + view all
(2020)
Estradiol and mortality in women with end-stage kidney disease.
Nephrology Dialysis Transplantation
, 35
(11)
pp. 1965-1972.
10.1093/ndt/gfaa126.
|
|
Rossignol, P;
Ruilope, LM;
Cupisti, A;
Ketteler, M;
Wheeler, DC;
Pignot, M;
Cornea, G;
... Lund, LH; + view all
(2020)
Recurrent hyperkalaemia management and use of renin–angiotensin–aldosterone system inhibitors: a European multi-national targeted chart review.
Clinical Kidney Journal
, 13
(4)
pp. 714-719.
10.1093/ckj/sfz129.
|
|
|
Shivakumar, O;
Sattar, N;
Wheeler, DC;
(2020)
Sodium-glucose cotransporter 2 inhibitor effects on cardiovascular outcomes in chronic kidney disease.
Nephrology Dialysis Transplantation
, 35
(S1)
i43-i47.
10.1093/ndt/gfz292.
|
|
Stefánsson, BV;
Heerspink, HJL;
Wheeler, DC;
Sjöström, CD;
Greasley, PJ;
Sartipy, P;
Cain, V;
(2020)
Correction of anemia by dapagliflozin in patients with type 2 diabetes.
Journal of Diabetes and its Complications
, 34
(12)
, Article 107729. 10.1016/j.jdiacomp.2020.107729.
|
|
Tong, A;
Levey, AS;
Eckardt, K-U;
Anumudu, S;
Arce, CM;
Baumgart, A;
Dunn, L;
... Winkelmayer, WC; + view all
(2020)
Patient and Caregiver Perspectives on Terms Used to Describe Kidney Health.
Clinical Journal of the American Society of Nephrology
, 15
(7)
pp. 937-948.
10.2215/CJN.00900120.
|
|
|
Wheeler, DC;
James, J;
Patel, D;
Viljoen, A;
Ali, A;
Evans, M;
Fernando, K;
... as part of the Improving Diabetes Steering Committee, .; + view all
(2020)
SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes.
Diabetes Therapy
10.1007/s13300-020-00930-x.
(In press).
|
|
|
Wheeler, DC;
Stefansson, BV;
Batiushin, M;
Bilchenko, O;
Cherney, DZI;
Chertow, GM;
Douthat, W;
... Heerspink, HJL; + view all
(2020)
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Nephrology Dialysis Transplantation
10.1093/ndt/gfaa234.
(In press).
|
|
2019
|
Chan, CT;
Blankestijn, PJ;
Dember, LM;
Gallieni, M;
Harris, D;
Lok, CE;
Mehrotra, R;
... Pollock, CA; + view all
(2019)
Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
, 96
(1)
pp. 37-47.
10.1016/j.kint.2019.01.017.
|
|
Cherney, DZI;
Repetto, E;
Wheeler, DC;
Arnold, SV;
MacLachlan, S;
Hunt, PR;
Chen, H;
... Kosiborod, M; + view all
(2019)
Impact of Cardio-Renal-Metabolic Comorbidities on Cardiovascular Outcomes and Mortality in Type 2 Diabetes Mellitus.
American Journal of Nephrology
, 51
pp. 74-82.
10.1159/000504558.
|
|
|
Cheung, AK;
Chang, TI;
Cushman, WC;
Furth, SL;
Ix, JH;
Pecoits-Filho, R;
Perkovic, V;
... Mann, JFE; + view all
(2019)
Blood pressure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
, 95
(5)
pp. 1027-1036.
10.1016/j.kint.2018.12.025.
|
|
Clase, CM;
Carrero, J-J;
Ellison, DH;
Grams, ME;
Hemmelgarn, BR;
Jardine, MJ;
Kovesdy, CP;
... Conference Participants, .; + view all
(2019)
Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
10.1016/j.kint.2019.09.018.
(In press).
|
|
|
Floege, J;
Barbour, S;
Cattran, DC;
Hogan, JJ;
Nachman, PH;
Tang, SCW;
Wetzels, JFM;
... Rovin, BH; + view all
(2019)
Management and Treatment of Glomerular Diseases (Part 1): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
, 95
(2)
pp. 268-280.
10.1016/j.kint.2018.10.018.
|
|
|
Ha, JT;
Neuen, BL;
Cheng, LP;
Jun, M;
Toyama, T;
Gallagher, MP;
Jardine, MJ;
... Badve, SV; + view all
(2019)
Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
Annals of Internal Medicine
, 171
(3)
pp. 181-189.
10.7326/M19-0087.
|
|
House, AA;
Wanner, C;
Sarnak, MJ;
Piña, IL;
McIntyre, CW;
Komenda, P;
Kasiske, BL;
... Weir, MR; + view all
(2019)
Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
, 95
pp. 1304-1317.
10.1016/j.kint.2019.02.022.
|
|
|
Idzerda, NMA;
Stefansson, BV;
Pena, MJ;
Sjostrom, DC;
Wheeler, DC;
Heerspink, HJL;
(2019)
Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.
Nephrology Dialysis Transplantation
10.1093/ndt/gfz064.
(In press).
|
|
Inker, LA;
Grams, ME;
Levey, AS;
Coresh, J;
Cirillo, M;
Collins, JF;
Gansevoort, RT;
... Surapaneni, A; + view all
(2019)
Relationship of Estimated GFR and Albuminuria to Concurrent Laboratory Abnormalities: An Individual Participant Data Meta-analysis in a Global Consortium.
American Journal of Kidney Diseases
, 73
(2)
pp. 206-217.
10.1053/j.ajkd.2018.08.013.
|
|
Lange Neuen, B;
Young, T;
Heerspink, H;
Neal, B;
Perkovic, V;
Billot, L;
Mahaffey, KW;
... Jardine, MJ; + view all
(2019)
SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
The Lancet Diabetes and Endocrinology
, 7
(11)
pp. 845-854.
10.1016/S2213-8587(19)30256-6.
|
|
Louie, KS;
Erhard, C;
Wheeler, DC;
Stenvinkel, P;
Fouqueray, B;
Floege, J;
(2019)
Cinacalcet-induced hypocalcemia in a cohort of European haemodialysis patients: predictors, therapeutic approaches and outcomes.
Journal of Nephrology
10.1007/s40620-019-00686-z.
(In press).
|
|
|
Macdougall, IC;
White, C;
Anker, SD;
Bhandari, S;
Farrington, K;
Kalra, PA;
McMurray, JJV;
... Ford, I; + view all
(2019)
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.
The New England Journal of Medicine
, 380
(5)
pp. 447-458.
10.1056/NEJMoa1810742.
|
|
Macdougall, IC;
White, C;
Anker, SD;
Bhandari, S;
Farrington, K;
Kalra, PA;
McMurray, JJV;
... Ford, I; + view all
(2019)
Intravenous Iron in Patients Undergoing Maintenance Hemodialysis [vol 380 (5), p502, 31 Jan 2019].
[Corrigendum].
New England Journal of Medicine
, 380
(5)
p. 502.
10.1056/NEJMoa1810742.
|
|
Mahaffey, KW;
Jardine, M;
Bompoint, S;
Cannon, C;
Bruce, N;
Herspink, LHJ;
Charytan, D;
... Perkovic, V; + view all
(2019)
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial.
Circulation
, 140
(9)
pp. 739-750.
10.1161/CIRCULATIONAHA.119.042007.
|
|
|
Marwick, TH;
Amann, K;
Bangalore, S;
Cavalcante, JL;
Charytan, DM;
Craig, JC;
Gill, JS;
... Zarbock, A; + view all
(2019)
Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
, 96
(4)
pp. 836-849.
10.1016/j.kint.2019.06.025.
|
|
|
Muskiet, M;
Wheeler, DC;
Heerspink, H;
(2019)
New pharmacological strategies for protecting kidney function in type 2 diabetes.
[Review].
The Lancet Diabetes and Endocrinology
, 7
(5)
pp. 397-412.
10.1016/S2213-8587(18)30263-8.
|
|
Perkovic, V;
Jardine, MJ;
Neal, B;
Bompoint, S;
Heerspink, HJL;
Charytan, DM;
Edwards, R;
... CREDENCE Trial Investigators, .; + view all
(2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
New England Journal of Medicine
, 380
(24)
pp. 2295-2306.
10.1056/NEJMoa1811744.
|
|
|
Pollock, C;
Stefánsson, B;
Reyner, D;
Rossing, P;
Sjöström, CD;
Wheeler, DC;
Langkilde, AM;
(2019)
Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
The Lancet Diabetes & Endocrinology
, 7
(6)
pp. 429-441.
10.1016/S2213-8587(19)30086-5.
|
|
Rovin, BH;
Caster, DJ;
Cattran, DC;
Gibson, KL;
Hogan, JJ;
Moeller, MJ;
Roccatello, D;
... Floege, J; + view all
(2019)
Management and Treatment of Glomerular Diseases (Part 2): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
, 95
(2)
pp. 281-295.
10.1016/j.kint.2018.11.008.
|
|
|
Sarnak, MJ;
Amann, K;
Bangalore, S;
Cavalcante, JL;
Charytan, DM;
Craig, JC;
Gill, JS;
... Zarbock, A; + view all
(2019)
Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.
Journal of the American College of Cardiology
, 74
(14)
pp. 1823-1838.
10.1016/j.jacc.2019.08.1017.
|
|
|
Schlackow, I;
Kent, S;
Herrington, W;
Emberson, J;
Haynes, R;
Reith, C;
Collins, R;
... Tomson, C; + view all
(2019)
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Kidney International
, 96
(1)
pp. 170-179.
10.1016/j.kint.2019.01.028.
|
|
|
Viecelli, AK;
Polkinghorne, KR;
Pascoe, EM;
Paul-Brent, P-A;
Hawley, CM;
Badve, SV;
Cass, A;
... Wheeler, DC; + view all
(2019)
Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial.
PLOS ONE
, 14
(3)
, Article e0213274. 10.1371/journal.pone.0213274.
|
|
|
Wang, AY-M;
Akizawa, T;
Bavanandan, S;
Hamano, T;
Liew, A;
Lu, K-C;
Lumlertgul, D;
... Fukagawa, M; + view all
(2019)
2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report.
Kidney International Reports
, 4
(11)
pp. 1523-1537.
10.1016/j.ekir.2019.09.007.
|
|
2018
|
Dekkers, CCJ;
Wheeler, DC;
Sjostrom, CD;
Stefansson, BV;
Cain, V;
Heerspink, HJL;
(2018)
Effects of the sodium–glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b–4 chronic kidney disease.
Nephrology Dialysis Transplantation
, 33
(11)
pp. 2005-2011.
10.1093/ndt/gfx350.
|
|
|
Eckardt, K-U;
Bansal, N;
Coresh, J;
Evans, M;
Grams, ME;
Herzog, CA;
James, MT;
... Conference Participants, .; + view all
(2018)
Improving the prognosis of patients with severely decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
10.1016/j.kint.2018.02.006.
(In press).
|
|
Evans, M;
Grams, ME;
Sang, Y;
Astor, BC;
Blankestijn, PJ;
Brunskill, NJ;
Collins, JF;
... Wheeler, DC; + view all
(2018)
Risk Factors for Prognosis in Patients With Severely Decreased GFR.
Kidney International Reports
, 3
(3)
pp. 625-637.
10.1016/j.ekir.2018.01.002.
|
|
|
Hull, SA;
Nitsch, D;
Caplin, B;
Griffith, K;
Wheeler, DC;
(2018)
The National CKD Audit: a primary care condition that deserves more attention.
[Editorial comment].
British Journal of General Practice
, 68
(673)
pp. 356-357.
10.3399/bjgp18X697997.
|
|
KDIGO Hepatitis C Work Group, .;
(2018)
KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease.
Kidney International Supplements
, 8
(3)
pp. 91-165.
10.1016/j.kisu.2018.06.001.
|
|
|
Macdougall, IC;
White, C;
Anker, SD;
Bhandari, S;
Farrington, K;
Kalra, PA;
McMurray, JJV;
... PIVOTAL Trial investigators, .; + view all
(2018)
Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.
American Journal of Nephrology
, 48
(4)
pp. 260-298.
10.1159/000493551.
|
|
|
Mafham, MM;
Staplin, N;
Emberson, J;
Haynes, R;
Herrington, W;
Reith, C;
Wanner, C;
... SHARP Collaborative Group, .; + view all
(2018)
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
Nephrology Dialysis Transplantation
, 33
(2)
pp. 257-264.
10.1093/ndt/gfw396.
|
|
|
Marthi, A;
Donovan, K;
Haynes, R;
Wheeler, DC;
Baignent, C;
Rooney, CM;
Landray, MJ;
... Herrington, W; + view all
(2018)
Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.
Journal of the American Society of Nephrology
, 29
(7)
pp. 2015-2027.
10.1681/ASN.2017121334.
|
|
O'Lone, E;
Viecelli, AK;
Craig, JC;
Tong, A;
Sautenet, B;
Roy, D;
Herrington, WG;
... Wheeler, DC; + view all
(2018)
Cardiovascular Outcomes Reported in Hemodialysis Trials.
Journal of the American College of Cardiology
, 71
(24)
pp. 2802-2810.
10.1016/j.jacc.2018.04.012.
|
|
|
Sautenet, B;
Tong, A;
Williams, G;
Hemmelgarn, BR;
Manns, B;
Wheeler, DC;
Tugwell, P;
... Craig, JC; + view all
(2018)
Scope and Consistency of Outcomes Reported in Randomized Trials Conducted in Adults Receiving Hemodialysis: A Systematic Review.
American Journal of Kidney Diseases
, 72
(1)
pp. 62-74.
10.1053/j.ajkd.2017.11.010.
|
|
Swanepoel, CR;
Atta, MG;
D'Agati, VD;
Estrella, MM;
Fogo, AB;
Naicker, S;
Post, FA;
... Wyatt, CM; + view all
(2018)
Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
, 93
(3)
pp. 545-559.
10.1016/j.kint.2017.11.007.
|
|
|
Tong, A;
Crowe, S;
Gill, JS;
Harris, T;
Hemmelgarn, B;
Manns, B;
Tugwell, P;
... Craig, J; + view all
(2018)
Clinicians' and researchers' perspectives on establishing and implementing core outcomes in haemodialysis: semistructured interview study.
BMJ Open
, 8
(4)
, Article e021198. 10.1136/bmjopen-2017-021198.
|
|
|
Tong, A;
Manns, B;
Wang, AYM;
Hemmelgarn, B;
Wheeler, DC;
Gill, J;
Tugwell, P;
... Craig, JC; + view all
(2018)
Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop.
Kidney International
, 94
(6)
pp. 1053-1068.
10.1016/j.kint.2018.08.018.
|
|
Turakhia, MP;
Blankestijn, PJ;
Carrero, JJ;
Clase, C;
Deo, R;
Herzog, CA;
Kasner, SE;
... Wanner, C; + view all
(2018)
Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
European Heart Journal
, 39
(24)
pp. 2314-2325.
10.1093/eurheartj/ehy060.
|
|
Verberne, WR;
Das-Gupta, Z;
Allegretti, AS;
Bart, HAJ;
van Biesen, W;
García-García, G;
Gibbons, E;
... Bos, WJW; + view all
(2018)
Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group.
American Journal of Kidney Diseases
10.1053/j.ajkd.2018.10.007.
(In press).
|
|
|
Wheeler, DC;
Haynes, R;
Judge, PK;
Staplin, N;
Herrington, WG;
Storey, BC;
Bethel, A;
... Baigent, C; + view all
(2018)
Effects of Sacubitril/Valsartan versus Irbesartan in patients with chronic kidney disease: a randomised double-blind trial.
Circulation
, 138
(15)
10.1161/CIRCULATIONAHA.118.034818.
|
|
|
Wheeler, DC;
Jardine, MJ;
Mahaffey, KW;
Neal, B;
Agarwal, R;
Bakris, G;
Brenner, BM;
... Perkovic, V; + view all
(2018)
The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale and design.
American Journal of Nephrology
, 46
(6)
pp. 462-472.
10.1159/000484633.
|
|
|
Wheeler, DC;
Kovesdy, C;
Matsushita, K;
Sang, Y;
Brunskill, NJ;
Carrero, JJ;
Chodick, G;
... Grams, ME; + view all
(2018)
Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis.
European Heart Journal
, 39
(17)
pp. 1535-1542.
10.1093/eurheartj/ehy100.
|
2017
|
Baigent, C;
Herrington, WG;
Coresh, J;
Landray, MJ;
Levin, A;
Perkovic, V;
Pfeffer, MA;
... McMurray, JJV; + view all
(2017)
Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
, 92
(2)
pp. 297-305.
10.1016/j.kint.2017.04.019.
|
|
Bello, AK;
Alrukhaimi, M;
Ashuntantang, GE;
Basnet, S;
Rotter, RC;
Douthat, WG;
Kazancioglu, R;
... Moe, O; + view all
(2017)
Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action.
[Review].
Kidney International Supplements
, 7
(2)
pp. 122-129.
10.1016/j.kisu.2017.07.007.
|
|
Caplin, BD;
Kim, L;
Cleary, F;
Hull, S;
Griffin, K;
Wheeler, D;
Nitsch, D;
(2017)
Accounting for overdispersion when determining primary care outliers for the identification of chronic kidney disease: learning from the National Chronic Kidney Disease Audit.
Nephrology, Dialysis and Transplantation
, 32
(Supp 2)
ii151-ii158.
10.1093/ndt/gfw398.
|
|
Evangelidis, N;
Tong, A;
Manns, B;
Hemmelgarn, B;
Wheeler, DC;
Tugwell, P;
Crowe, S;
... Craig, JC; + view all
(2017)
Developing a Set of Core Outcomes for Trials in Hemodialysis: An International Delphi Survey.
American Journal of Kidney Diseases
, 70
(4)
pp. 464-475.
10.1053/j.ajkd.2016.11.029.
|
|
Hayer, MK;
Edwards, NC;
Slinn, G;
Moody, WE;
Steeds, RP;
Ferro, CJ;
Price, AM;
... Townend, JN; + view all
(2017)
A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial.
American Heart Journal
, 191
(C)
pp. 37-46.
10.1016/j.ahj.2017.05.008.
|
|
|
Levin, A;
Tonelli, M;
Bonventre, J;
Coresh, J;
Donner, J-A;
Fogo, AB;
Fox, CS;
... ISN Global Kidney Health Summit participants; + view all
(2017)
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.
The Lancet
, 390
(10105)
pp. 1888-1917.
10.1016/S0140-6736(17)30788-2.
|
|
Luyckx, VA;
Tuttle, KR;
Garcia-Garcia, G;
Gharbi, MB;
Heerspink, HJL;
Johnson, DW;
Liu, Z-H;
... White, SL; + view all
(2017)
Reducing major risk factors for chronic kidney disease.
[Review].
Kidney International Supplements
, 7
(2)
pp. 71-87.
10.1016/j.kisu.2017.07.003.
|
|
Ramesh, S;
James, MT;
Holroyd-Leduc, JM;
Wilton, SB;
Seely, EW;
Wheeler, DC;
Ahmed, SB;
(2017)
Sex Hormone Status in Women With Chronic Kidney Disease: Survey of Nephrologists' and Renal Allied Health Care Providers' Perceptions.
Can J Kidney Health Dis
, 4
10.1177/2054358117734534.
|
|
|
Storey, BC;
Staplin, N;
Haynes, R;
Reith, C;
Emberson, J;
Herrington, WG;
Wheeler, DC;
... SHARP Collaborative Group, .; + view all
(2017)
Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.
Kidney International
10.1016/j.kint.2017.09.011.
|
|
|
Tomlinson, JAP;
Wheeler, DC;
(2017)
The role of trimethylamine N-oxide as a mediator of cardiovascular complications in chronic kidney disease.
Kidney International
, 92
(4)
pp. 809-815.
10.1016/j.kint.2017.03.053.
|
|
Tong, A;
Craig, JC;
Nagler, EV;
Van Biesen, W;
Manns, B;
Hemmelgarn, B;
Wheeler, DC;
... Zoccali, C; + view all
(2017)
Composing a new song for trials: the Standardized Outcomes in Nephrology (SONG) initiative.
Nephrology Dialysis Transplantation
, 32
(12)
pp. 1963-1966.
10.1093/ndt/gfx288.
|
|
Wheeler, DC;
Lv, J;
Zhang, H;
Wong, MG;
Jardine, MJ;
Hladunewich, M;
Jha, V;
... Perkovic, V; + view all
(2017)
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.
JAMA - Journal of the American Medical Association
, 318
(5)
pp. 432-442.
10.1001/jama.2017.9362.
|
|
Wheeler, DC;
Bello, AK;
Alkhaim, M;
Ashuntantang, G;
Basnet, S;
Rotter, RC;
Douthat, W;
... Moe, O; + view all
(2017)
Complications of CKD: current state, knowledge gaps, and strategy for action.
Kidney International Supplements
, 7
(2)
pp. 122-129.
10.1016/j.kisu.2017.07.007.
|
|
Wheeler, DC;
Bockenhauer, D;
Day, S;
Devuyst, O;
Guay-Woodford, LM;
Ingelfinger, JR;
Klein, JB;
... Winkelmayer, W; + view all
(2017)
Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
Kidney International
, 92
(4)
pp. 796-808.
10.1016/j.kint.2017.06.018.
|
|
|
Wheeler, DC;
Kim, LG;
Cleary, F;
Caplin, B;
Nitsch, D;
Hull, SA;
(2017)
How do primary care doctors in England and Wales code and manage people with chronic kidney disease? Results from the National Chronic Kidney Disease Audit.
Nephrology Dialysis Transplantation
10.1093/ndt/gfx280.
|
|
Wheeler, DC;
Tong, A;
Wolfgang, C;
van Biesen5, W;
Tugwell, P;
Manns, B;
Hemmelgarn, B;
... Craig, JC; + view all
(2017)
Nephrologists' perspectives on defining and applying patient-centered outcomes in hemodialysis.
Clinical Journal of the American Society of Nephrology
, 12
(3)
pp. 454-466.
10.2215/CJN.08370816.
|
|
|
Wheeler, DC;
Winkelmayer, WC;
(2017)
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Foreword.
Kidney International Supplements
, 7
(1)
pp. 1-59.
10.1016/j.kisu.2017.04.001.
|
|
2016
|
Evangelidis, N;
Tong, A;
Manns, B;
Hemmelgarn, B;
Wheeler, D;
Tugwell, P;
Crowe, S;
... Craig, J; + view all
(2016)
Developing a Set of Core Outcomes for Trials in Haemodialysis: An International Delphi Survey.
In:
(Proceedings) The 15th Asian Pacific Congress of Nephrology (APCN) and 52nd ANZSN ASM, 17–21 September 2016, Perth Convention and Exhibition Centre, Western Australia.
(pp. p. 119).
Wiley-Blackwell
|
|
Herrington, W;
Staplin, N;
Judge, PK;
Mafham, M;
Emberson, J;
Haynes, R;
Wheeler, DC;
... SHARP Collaborative Group, .; + view all
(2016)
Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.
Hypertension
, 69
(2)
pp. 314-322.
10.1161/HYPERTENSIONAHA.116.08386.
|
|
|
Jha, V;
Arici, M;
Collins, AJ;
Garcia-Garcia, G;
Hemmelgarn, BR;
Jafar, TH;
Pecoits-Filho, R;
... Conference Participants; + view all
(2016)
Understanding kidney care needs and implementation strategies in low- and middle-income countries: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Kidney International
, 90
(6)
pp. 1164-1174.
10.1016/j.kint.2016.09.009.
|
|
|
Judge, PK;
Haynes, R;
Herrington, WG;
Storey, BC;
Staplin, N;
Bethel, A;
Bowman, L;
... Baigent, C; + view all
(2016)
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III-rationale, trial design and baseline data.
Nephrology Dialysis Transplantation
, 32
(12)
pp. 2043-2051.
10.1093/ndt/gfw321.
|
|
|
Mann, MC;
Exner, DV;
Hemmelgarn, BR;
Hanley, DA;
Turin, TC;
MacRae, JM;
Wheeler, DC;
... Ahmed, SB; + view all
(2016)
The VITAH Trial-Vitamin D Supplementation and Cardiac Autonomic Tone in Patients with End-Stage Kidney Disease on Hemodialysis: A Blinded, Randomized Controlled Trial.
Nutrients
, 8
(10)
, Article 608. 10.3390/nu8100608.
|
|
Parfrey, PS;
Block, GA;
Correa-Rotter, R;
Drueke, TB;
Floege, J;
Herzog, CA;
London, GM;
... Chertow, GM; + view all
(2016)
Lessons learned from EVOLVE for the planning of future global randomized trials in chronic kidney disease.
Clinical Journal of the American Society of Nephrology
, 11
(3)
pp. 539-546.
10.2215/CJN.06370615.
|
|
Perkovic, V;
Agarwal, R;
Fioretto, P;
Hemmelgarn, BR;
Levin, A;
Thomas, MC;
Wanner, C;
... Conference Participants; + view all
(2016)
Management of patients with diabetes and CKD: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.
Kidney International
, 90
(6)
pp. 1175-1183.
10.1016/j.kint.2016.09.010.
|
|
|
Staplin, N;
Haynes, R;
Herrington, WG;
Reith, C;
Cass, A;
Fellström, B;
Jiang, L;
... SHARP Collaborative Group, .; + view all
(2016)
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).
American Journal of Kidney Diseases
, 68
(3)
pp. 371-380.
10.1053/j.ajkd.2016.02.052.
|
|
Tong, A;
Budde, K;
Gill, J;
Josephson, MA;
Marson, L;
Pruett, TL;
Reese, PP;
... Chapman, JR; + view all
(2016)
Standardized Outcomes in Nephrology-Transplantation: A Global Initiative to Develop a Core Outcome Set for Trials in Kidney Transplantation.
Transplantation Direct
, 2
(6)
, Article e79. 10.1097/TXD.0000000000000593.
|
|
|
Tong, A;
Manns, B;
Hemmelgarn, B;
Wheeler, DC;
Evangelidis, N;
Tugwell, P;
Crowe, S;
... SONG-HD Investigators, .; + view all
(2016)
Establishing Core Outcome Domains in Hemodialysis: Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop.
American Journal of Kidney Diseases
, 69
(1)
pp. 97-107.
10.1053/j.ajkd.2016.05.022.
|
|
Tong, A;
Samuel, S;
Zappitelli, M;
Dart, A;
Furth, S;
Eddy, A;
Groothoff, J;
... Craig, JC; + view all
(2016)
Standardised Outcomes in Nephrology-Children and Adolescents (SONG-Kids): a protocol for establishing a core outcome set for children with chronic kidney disease.
Trials
, 17
, Article 401. 10.1186/s13063-016-1528-5.
|
|
|
Wheeler, DC;
Kasiske, BL;
(2016)
Statins for hemodialysis patients with diabetes? Long-term follow-up endorses the original conclusions of the 4D Study.
Kidney International
, 89
(6)
pp. 1189-1191.
10.1016/j.kint.2016.02.045.
|
2015
|
Tomlinson, JAP;
Caplin, BD;
Boruc, O;
Bruce-Cobbold, C;
Cutillas, P;
Dormann, D;
Faull, P;
... Leiper, J; + view all
(2015)
Reduced renal methylarginine metabolism protects against progressive kidney damage.
Journal of the American Society of Nephrology
, 26
(12)
pp. 3045-3059.
10.1681/ASN.2014030280.
|
|
2014
|
Moe, SM;
Abdalla, S;
Chertow, GM;
Parfrey, P;
Block, GA;
Correa-Rotter, R;
Floege, J;
... Drüeke, TB; + view all
(2014)
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE Trial.
Journal of the American Society of Nephrology
, 26
(6)
pp. 1466-1475.
10.1681/ASN.2014040414.
|
|
|
Power, A;
Fogarty, D;
Wheeler, DC;
(2014)
Acute stroke thrombolysis in end-stage renal disease: a national survey of nephrologist opinion.
Nephron Clinical Practice
, 124
(3-4)
pp. 167-172.
10.1159/000357155.
|
2013
|
Caplin, B;
Veighey, K;
Mahenderan, A;
Manook, M;
Henry, J;
Nitsch, D;
Harber, M;
... Veitch, P; + view all
(2013)
Early changes in scores of chronic damage on transplant kidney protocol biopsies reflect donor characteristics, but not future graft function.
Clin Transplant
, 27
(6)
E669-E678.
10.1111/ctr.12251.
|
|
2006
|
Ruan, XZ;
Moorhead, JF;
Tao, JL;
Ma, KL;
Wheeler, DC;
Powis, SH;
Varghese, Z;
(2006)
Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatory cytokines.
ARTERIOSCL THROM VAS
, 26
(5)
1150 - 1155.
10.1161/01.ATV.0000217957.93135.c2.
|
|
